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SUMMARY 
The prion protein (PrP) is currently one of the most studied molecules in the neurosciences as it 
causes a group of neurological diseases collectively named transmissible spongiform 
encephalophaties (TSEs). The TSEs are characterized by a variety of motor and/or cognitive 
symptoms distinct from those of Parkinson and Alzheimer diseases and severely affect both humans 
and a variety of mammals. A great effort has thus been made to understand the molecular basis of 
PrP activity, both in physiological and pathological terms. In this context, the identification of 
neuronally-relevant interactors of PrP, capable of governing or interfering with its activity, cellular 
localization and/or expression, plays a crucial role. Through the expression of the proteins of 
interest in recombinant form in E.coli cells and the analysis of their interaction by Western blot and 
dot-blot, we identified two specific and neurologically relevant interactions involving the prion 
protein and on the one hand tyrosine hydroxylase, the enzyme that catalyzes the initial and rate-
limiting reaction of the biosynthesis of catecholamines dopamine, norepinephrine and epinephrine; 
on the other hand the heat shock protein B8, member of the small heat shock protein family that 
appears to play an important role in those diseases that, like transmissible spongiform 
encephalopathies, are characterized by the accumulation of misfolded proteins. The 
association/dissociation constants of the complexes have been calculated using surface plasmon 
resonance and interactions were confirmed by immunohistochemistry. The data obtained show a 
specific and high affinity interaction (KD in the nano molar range) between the TH N-terminal 
regulatory domain (1-152) and the C-terminal structured domain (90-230) of PrP. The co-
expression of the two proteins causes a shift in prion protein expression from a prevalent 
membrane-associated expression to a greater cytoplasmic localization, and also a down-regulation 
of the levels of expression of the prion protein without, however, affecting the topology and 
expression of tyrosine hydroxylase. The link between PrP and HSPB8 involves the C-terminal 
domain of the prion protein and the co-expression of the two proteins leads to a down-regulation of 
both prion protein and HSPB8. The latter, moreover, protects the prion protein from degradation by 
Proteinase K, while it seems to accelerate the thermal denaturation. The mutants K141E and K141N 
of the heat shock protein, associated with the development of neuropathy, show minor binding 
affinity with respect to the wild type protein and they are less effective in regulating the levels of 
expression, localization and degradation of the prion protein. Our results, in particular if confirmed 
in pathological patterns, can help to understand the physiological and pathological mechanisms of 
action of the prion protein and suggest tyrosine hydroxylase and heat shock protein B8 as prion 
protein modulators, thus as potential targets for therapeutic applications. 
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SOMMARIO 
La proteina prionica è, ad oggi, una delle molecole più studiate nelle neuroscienze poiché essa 
rappresenta l’agente eziologico di un gruppo di patologie neurologiche chiamate collettivamente 
encefalopatie spongiformi trasmissibili (TSE). Queste patologie sono caratterizzate da una serie di 
sintomi motori e cognitivi distinti da quelli delle patologie di Parkinson e Alzheimer e colpiscono 
l’uomo e una grande varietà di mammiferi. Per tale ragione un grande sforzo è stato fatto per capire 
le basi molecolari dell’attività di PrP in condizioni fisiologiche e patologiche, le quali, tutt’ora, non 
sono del tutto comprese. In questo contesto è di cruciale importanza l’identificazione di nuovi 
partner di legame che regolino o interferiscano con l’attività, la localizzazione cellulare e/o 
l’espressione della proteina prionica. Tramite l’espressione delle proteine di interesse in forma 
ricombinante in cellule di E.coli e l’analisi delle loro interazioni mediante Western blot e dot-blot, 
abbiamo identificato due interazioni specifiche e neurologicamente rilevanti della proteina prionica 
coinvolgenti da un lato la tirosina idrossilasi, enzima che catalizza la reazione iniziale e limitante 
della biosintesi delle catecolamine dopamina, norepinefrina ed epinefrina; dall’altro l’heat shock 
protein B8, membro della famiglia delle small heat shock protein, che sembra ricoprire un ruolo 
particolarmente importante in quelle patologie che, come le encefalopatie spongiformi trasmissibili, 
sono caratterizzate dall’accumulo di proteine mal ripiegate. Le costanti di 
associazione/dissociazione dei complessi sono state calcolate mediante surface plasmon resonance e 
le interazioni sono state confermate tramite immunoistochimica. I dati ottenuti evidenziano 
un’interazione specifica e ad alta affinità (KD nel range nM) tra il dominio regolatorio N-terminale 
(1-152) di TH e il dominio strutturato C-terminale (90-230) di PrP. La co-espressione delle due 
proteine causa sia uno spostamento da un’espressione prevalentemente di membrana della proteina 
prionica ad una localizzazione maggiormente citoplasmatica, sia una down-regolazione dei livelli di 
espressione di proteina prionica senza, tuttavia, influenzare topologia ed espressione della tirosina 
idrossilasi. Il legame tra PrP e HSPB8 coinvolge il dominio C-terminale della proteina prionica e la 
co-espressione delle due proteine porta ad una down-regolazione sia di proteina prionica che di 
HSPB8. Quest’ultima, inoltre, protegge la proteina prionica dalla degradazione da parte di 
proteinasi K, mentre sembra favorirne la denaturazione termica. I mutanti K141E e K141N 
dell’heat shock protein, associati allo sviluppo di neuropatie, mostrano affinità di binding minori 
rispetto alla proteina wild type così come sono meno efficaci nel regolare i livelli di espressione, 
localizzazione e degradazione della proteina prionica.  I nostri risultati, in particolare se confermati 
in modelli di patologia, possono aiutare a comprendere i meccanismi  d’azione fisiologici  e 
patologici della proteina prionica e indicano tirosina idrossilasi e heat shock protein B8 come 
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modulatori della proteina prionica stessa e quindi come potenziali target per applicazioni 
terapeutiche. 
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INTRODUCTION 
The prion protein 
The prion protein is a glycoprotein that is expressed most abundantly in the brain, but has also been 
detected in other non-neuronal tissues as diverse as lymphoid cells, lung, heart, kidney, 
gastrointestinal tract, muscle, and mammary glands (Horiuchi et al. 1995). The prion protein is, to 
date, one of the most studied proteins due to its role in several neurological diseases collectively 
named TSE (transmissible spongiform encephalopathies). 
The term “prion” was first used by Stanley B. Prusiner in 1982 to denote the infectious pathogen   
causing scrapie of sheep  and  goats. This new small proteinaceous infectious particle was different 
from viruses, plasmids and viroids and was extremely resistant to inactivation by most procedures 
that modify nucleic acid (Prusiner 1982). 
PrP may exist in two isoforms: a normal cellular prion protein designated as PrP
C
 and a pathogenic 
misfolded conformer called PrP
SC
. The superscript (SC) has been used to refer to scrapie, the first 
and the most ancient animal transmissible spongiform encephalopathy (TSE). Many authors also 
use superscripts other than (SC) to distinguish normal and  pathogenic  (disease-causing)  isoforms.  
These include (Res) for resistant and (Dis) for disease. An abbreviated name of a prion disease can 
also be used as superscript to point out the origin of the pathogenic isoform (PrP
SC
 or PrP
CJD
). The 
pathogenic conformers are simply called prions (Prusiner 1998). 
 
The PrP gene 
Both PrP
C
 and PrP
SC
 are encoded from the same sequence of a 16 Kb single copy PRNP gene, 
which is a member of the PRN gene family that also includes PRND, encoding the doppel protein 
(Moore et al. 1999), and SPRN, encoding shadoo (Watts and Westaway 2007). The PRN gene is 
positioned at the short (p) arm of human chromosome 20 (20p13) from base pair 4,666,796 to 
4,682,233. The entire ORF of PrP is contained in a single exon in all species although the gene 
itself comprises  two  to  three  exons  ruling out the possibility that PrP
C
 and PrP
SC
 differ  by   
alternative mRNA splicing (Stahl and Prusiner 1991). The other exons contain untranslated 
sequences including the promoter and termination sites. The PrP promoter contains multiple copies 
of GC rich repeats that may function as a canonical binding site for the transcription factor Sp1 
(McKnight and Tjian 1986). The alignment of the translated sequences from more than 40 PrP 
genes shows a striking degree of conservation between the mammalian sequences,  suggesting  the  
retention  of  some important function for PrP through evolution. However, variations in PrP 
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sequences exist both between species and between individuals within species (Colby and Prusiner 
2011). 
 
The PrP structure 
The abnormal PrP
SC
 differs from the normal PrP
C 
isoform in secondary and tertiary structure but not 
in primary amino acids sequence. The primary sequence of PrP is 253 amino acids long before post 
translational modification. The protein is synthesized with a NH2-terminal signal sequence that 
targets it to the endoplasmic reticulum where the  peptide is removed, leaving Lys23 as the amino-
terminal residue (Turk et al. 1988).  The last 23 COOH-terminal amino acids are cleaved off after 
the addiction of a glycosylphosphatidylinositol (GPI) anchor which helps the protein to attach to the 
outer surface of cells membrane. The mature primary sequence of the prion protein is so composed 
of 208 amino acids. For human and Syrian hamster PrP, two glycosylated sites exist on helices 2 
and 3 at Asn181 and Asn197. Murine PrP has glycosylation sites as Asn180 and Asn196. No post-
translational modifications to the primary structure differentiate PrP
C
 from PrP
SC
  (Stahl et al. 
1993). 
The nuclear magnetic resonance (NMR) structures for normal PrP of some species, such as mice, 
humans, Syrian hamsters and cattle, have been successfully illustrated, sharing common features. 
The mature PrP
C
 consists of a long flexible amino-terminal tail of about 100 amino acids (residues 
23-128) and a C-terminal domain, also of around 100 amino acids. 
 The C-terminal domain is composed largely of α-helical structure with three α-helices and  a  short  
anti-parallel  β-sheet. The second β-sheet and the third α-helix are connected by a large loop with 
interesting structural properties. The carboxyl terminus of PrP
C
 is stabilized by a disulfide bond that 
links helices two and three and exhibits a globular structure. A crystal structure of PrP has been 
obtained, largely in agreement with the NMR structures (Antonyuk et al. 2009). 
 
Fig:1. Model of the C-terminal domain of human prion protein 
indicating positions of N-linked glycans, the single disulphide bond 
joining helices 2 and 3, and the GPI anchor which attaches the protein to 
the outer surface of the cell membrane (Collinge 2005). 
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The N-terminal unstructured domain contains two defined and conserved region (Zahn et al. 2000). 
The first consists of a segment of five repeats of eight amino acids sequence, called the octapeptide 
repeat region. Mutations in this  region,  resulting  in  addition  of  integral  numbers  of additional 
repeats, lead to forms of inherited prion disease. This region is very highly conserved in evolution 
and contains two tight binding sites for Cu
2+ 
ions. It is proposed that the unstructured N-terminal 
region  may acquire   structure following copper binding and a role for PrP in copper metabolism or 
transport is possible.  Disturbance of this function by the conformational transitions between 
isoforms of PrP could be involved in prion related neurotoxicity (Jackson et al. 2001). The second 
region contains a highly hydrophobic and conserved profile, which is proposed to be the 
transmembrane region of the PrP molecule. In addition, the region around histidine-96 in PrP is 
believed to be the binding site for manganese and zinc, which may also contribute to the 
pathogenesis of prion diseases (Tian and Dong 2013). 
 
 
Fig: 2. Cartoon of the three-dimensional structure of the intact human prion protein, hPrP(23±230). The helices are orange, the β-
strands cyan, the segments with non-regular secondary structure within the C-terminal domain yellow, and the flexibly disordered 
“tail'' of residues 23±121 is represented by yellow dots (Zahn et al. 2000). 
 
PrP isoforms 
A post-translation chemical modification that distinguishes PrP
C
 and PrP
SC
 was considered but no 
one was found. To date, the most validate hypothesis is that they differed only in their 
conformation. Fourier-transform infrared (FTIR) spectroscopy and circular dichroism 
measurements demonstrate that PrP
C
 has a high α-helix content (42%) and no β-sheet (3%). In 
contrast, the β-sheet content of PrPSC is 43% and the α-helix is 30% (Pan et al. 1993). This 
conformational discrepancy renders the PrP
SC 
isoform extremely resistant to proteolysis. This    
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enhanced resistance of  PrP
SC
 to protease digestion is a cardinal feature that distinguishes it from    
PrP
C
. Whereas PrP
C
 is completely degraded upon incubation with proteinase K, PrP
SC
 loses an  
NH2-terminal domain containing the octarepeats. The cleavage site of protease usually locates 
around the residue 90 and produces a 90-231 core which has an apparent molecular mass of 27-30 
KDa, therefore referred as PrP 27-30 (Prusiner et al. 1984). The   PrP 27-30 has an even higher β-
sheet content (54%) and a lower α-helix content (21%) (Pan et al. 1993).  
 
 
Fig: 3. Scheme of the PRNP gene and PrP isoforms (Colby and Prusiner 2011). 
Furthermore, Prp
C 
is soluble in the presence of various detergents whereas PrP
SC
 forms insoluble 
aggregates, polymerizing into amyloid (Meyer et al. 1986). 
The prion topology 
During normal expression, PrP
C
 is translocated into the endoplasmic reticulum (ER) lumen, where 
it undergoes several  post-translational modifications, including the addition of the GPI anchor, 
disulfide bond formation, and core glycosylation at two asparagines, before it passes to the Golgi 
apparatus for further sugar modification and subsequently been attached to the outer leaflet of the 
plasma membrane (Norstrom et al. 2007). However, additional forms of PrP have been identified, 
including two transmembrane forms.  
Two distinct forms of PrP can be made at the ER: one that is fully translocated (
sec
PrP) and one that 
is transmembrane. Digestion of the transmembrane form with proteases added to the outside of the 
membrane yielded two fragments: one is COOH-terminal derived and glycosylated, and the other is 
NH2-terminal derived and unglycosylated. These data have been interpreted to indicate that 
transmembrane PrP chains span the membrane twice, with the NH2- and COOH-termini of the 
molecule in the ER lumen, protected from proteases added to the cytosolic side. However, the 
findings suggest that the NH2- and COOH-terminal fragments reflect the existence of two different 
transmembrane forms of PrP. One form, termed C-trans transmembrane (
Ctm
PrP), has the COOH-
terminus in the ER lumen with the NH2-terminus accessible to proteases in the cytosol. The other 
form, termed N-trans transmembrane (
Ntm
PrP), has the NH2-terminus in the ER lumen with the 
COOH-terminus accessible to proteases in the cytosol. Both transmembrane forms appear to span 
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the membrane at the same hydrophobic stretch in PrP (roughly residues 110 to 135, termed TM1). 
For this reason, the proteolytic fragments derived from each transmembrane form share a common 
domain of PrP approximately from residues 105 to 140 (the residues immediately adjacent to the 
membrane-spanning domain are not digested by protease, perhaps because of steric hindrance by 
the membrane itself) (Hegde et al. 1998). 
 
 
Fig: 4. The three topologic forms of PrP are shown before (left) and after (right) digestion with cytosolically disposed PK (Hegde et 
al. 1998). 
 
Moreover, cytosolic PrP form has been identified in subpopulations of neurons in the hippocampus, 
neocortex, and thalamus (Mironov et al. 2003, Fioriti et al. 2005, Ma et al. 2002) in a variety of 
condition including stress (Orsi et al. 2006). The role of cytosolic PrP is not clear but has been 
postulated to  have  an  anti-apoptotic  function (Roucou et al. 2003). 
Trafficking of PrP
C
 seems to be a complex cellular event and may involve more than one 
internalization mechanism. PrP
C
 is enriched in caveolae-like (raft) both at the transgolgi network 
and plasma membrane and  in  interconnecting  chains  of  endocytic caveolae-like domains. It is 
delivered via caveolae-like domains to the  pericentricolar  region  and  via  non-classical,  caveolae 
containing  early  endocytic structures  to  late endosomes/lysosomes (Zomosa-Signoret et al. 2008). 
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Fig: 5. Subcellular trafficking of PrPC (Linden et al. 2008). 
 
Prion protein physiological roles 
Although PrP is one of the most studied proteins, it is expressed in most tissue and it’s highly 
conserved among species, its cellular role is not completely understood. However, in the last few 
years, some possible biological functions for the cellular prion protein have been described.  
It is well known that PrP binds copper through its N-terminal domain containing octapeptide 
repeats. There is increasing evidence to support a functional role for PrP
C
 in copper metabolism and 
several groups have investigated the physiological meaning  of  this  association. PrP
C
 may be a 
principal copper-binding protein in brain membrane fractions and controls the activity of other 
membrane-associated copper-binding proteins. Prion protein expression alters copper uptake into 
cells and enhances copper incorporation into superoxide dismutase (SOD) (Zomosa-Signoret et al. 
2008). This copper-binding activity may be linked with a role in oxidative stress homeostasis. PrP, 
in fact, can act as a SOD (Brown et al. 1999) and PrP null cells are more susceptible to oxidative  
damage  and  toxicity  caused  by  agents such as copper and hydrogen peroxide (Brown et al. 
1998). It  also seems that the copper binding on the N-terminal domain of the prion protein can 
enable the recruitment of Phosphatidylinositol 3-kinase (PI 3-kinase) by PrP
C
. PI 3-kinase is  a  
protein  kinase  that  plays  a  pivotal  role in many cellular processes including cell survival  and  
apoptosis. Both mouse neuroblastoma N2a cells and immortalized murine hippocampal neuronal 
cell lines expressing wild-type PrP
C
 had a significantly higher PI 3-kinase activity levels than their 
respective controls (Vassallo et al. 2005). Many other signal transduction pathways have been 
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associated with PrP, mainly due to its localization in lipid rafts. A few studies provided evidence 
that PrP
C
 may lead to activation of Protein Kinase C (PKC) (Botto et al. 2004); treatment  of  
developing  retinal  tissue  with  PrP
C
 binding  peptides  led  to  activation  of  Erk  (Chiarini et al. 
2002); a  caveolin-dependent  coupling  of  PrP
C
 to  the  tyrosine  kinase  fyn  was  shown 
(Mouillet-Richard et al 2000) and  direct evidence that PrP
C
 mediates activation of the 
cAMP/protein kinase A (PKA) pathway was obtained with a peptide that binds PrP
C
 (Martins et al. 
1997). Moreover cells transfected with PRNP presented an increased agonist-induced calcium 
influx through the plasma membrane, while reducing the release of Ca
2+
  from the ER and Ca
2+ 
uptake by mitochondria  (Brini et al 2005). 
An anti-apoptotic role for the cellular prion protein has also been described. PrP
C
 protects against 
Bax-mediated neuronal apoptosis and potently inhibits Bax-induced cell death in human primary  
neurons, probably acting as a member of the Bcl-2 family.  Deletion  of  four  octapeptide repeats of 
PrP as well as familial D178N and T183A PrP mutations completely or partially suppress the 
neuroprotective effect of PrP (Bounhar et al. 2001). 
Lots of data show that PrP
C
 may play important roles in the development and  maintenance  of  the  
immune  system,  as  well as in specific cellular immunological  responses. A possible involvement 
of PrP
C
 in T cell activation leading to Th1 response has been proposed (Martínez del Hoyo et al. 
2006); PrP
C 
seems to support self-renewal of hematopoietic stem cells (HSC) (Zhang et al. 2006); 
PrP
C 
is down-regulated upon differentiation along the granulocyte lineage while maturation of 
monocyte and dendritic cells leads to PrP
C 
up-regulation (Zomosa-Signoret et al. 2008). 
 The fact that the protein is expressed in neurons  at  higher  levels  than  in  any  other  cell type  
suggests  that  PrP
C
  has  special  importance in neurons. PrP
C 
 is both pre-sinaptic (Herms et al. 
1999) and post-sinaptic. Several experimental observations suggest that PrP
C 
 could play a role in 
synaptic structure, function or maintenance. PrP
−/−
 mice have been reported to display several 
neurobiological abnormalities that may also relate to the participation of PrP
C
 in synapse formation 
and function. These include alterations in nerve fiber organization, circadian rhythm and spatial 
learning (Zomosa-Signoret et al. 2008). 
 
Prion propagation and toxicity 
According to the “protein only hypothesis”, prion propagation requires the conversion of PrPC to 
PrP
SC
, the anomalous conformer resulting from the shift from a predominantly α-helical structure 
into a predominantly β-sheet structure. This hypothesis was strongly supported by the fact that 
PRNP
0/0
 mice, not expressing the cellular prion protein, remain free of scrapie symptoms (Büeler et 
al. 1993). The β-sheet conformer is prone to form compact protein aggregates that accumulate 
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within the brain.  It has been proposed that the conversion of PrP
C
 to PrP
SC 
may also require the 
assistance of one or more as-yet-unidentified cofactors provisionally designated protein X. 
Presumably, protein X binds to PrP
C 
and enables it to interact with PrP
SC 
for conversion. Over 
expression of protein X would thus shorten incubation times for disease, whereas ablation of protein 
X would prolong or abolish prion disease. Many putative protein X genes have been identified, but 
transgenic knockouts for these genes have failed to alter incubation times (Prusiner et al. 2011). The 
precise sub cellular localization of the conversion from PrP
C 
isoform to PrP
SC 
is not well understood 
but it seems possible that it may in the late-endosome like organelles or lysosomes. The 
environments of these organelles facilitate protein unfolding at low pH and it is possible that the 
conversion from the physiological to the pathological isoform is caused by reduction and mild 
acidification (Collinge 2005).  
There are two models to explain the conformational conversion of PrP
C
 into PrP
SC. The “template-
directed refolding”  hypothesis  predicates  an  instructionist  role  for PrPSC on PrPC. Alternatively, 
the seeded nucleation hypothesis suggests that PrP
SC
 exists in equilibrium with PrP
C
. In a non-
disease state, such an equilibrium would be heavily shifted toward the PrP
C
 conformation,  such  
that  only  minute  amounts  of  PrP
SC
 would coexist with PrP
C
. If this were the case, PrP
SC
 could 
not possibly represent the infectious agent, since it would be ubiquitous. According to this “seeded 
nucleation” hypothesis, the infectious agent would consist  of  a  highly  ordered  aggregate  of  
PrP
SC
 molecules. The aggregated state would be an intrinsic property of infectivity. Monomeric 
PrP
SC
 would be harmless, but  it  might  be  prone  to  incorporation  into  nascent PrP Sc aggregates 
(Aguzzi and Calella 2009). 
 
     
Fig: 6. Models for conformational conversion from PrPC into PrPSC. A) template-directed refolding hypothesis; B) seeded nucleation 
hypothesis (Aguzzi and Calella 2009). 
 
The molecular mechanisms leading to cerebral damage are mostly unknown. Recent data suggest 
two major ways for PrP to cause toxicity in the brain: a gain of function hypothesis and a loss of 
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function hypothesis. According to the gain of function hypothesis PrP
SC
 aggregation sensitizes 
neurons to programmed cell death and leads to prion disease. The loss of function hypothesis is 
based on the idea that the toxicity of PrP
SC 
depends on the loss of cellular PrP or the alteration of 
some PrP
C
 dependent process culminating in neuronal dysfunction and death. 
It has also been suggested that the formation of amyloid fibrils, as  with other diseases characterized 
by protein aggregation, might be a protective process that sequesters the more dangerous 
subfibrillars oligomers or protein  into relatively innocuous deposits (Aguzzi and Calella 2009).  
 
 
Fig: 7. Schematic representation of the gain of function and loss of function hypothesis of  prion diseases (Linden et al. 2008).  
 
Transmissible spongiform encephalopathies 
The key features of nearly all prion diseases are transmissibility and a foamy pattern (spongiosis) of 
brain tissue that is visible on histological sections. Spongiosis is due primarily to intraneuronal 
vacuoles containing membrane fragments and, sometimes, degenerating organelles, but the etiology 
of this highly characteristic pathology is unclear. 
Prion diseases occur as sporadic, genetic, and transmissible  diseases  in  humans. 
Kuru, Creutzfeldt-Jakob disease (CJD), and Gerstmann-Straussler- Scheinker syndrome (GSS), are 
all human neurodegenerative diseases  that  are caused  by  prions  and  are frequently transmissible 
to laboratory animals. Individuals at risk can often  be  identified decades  in advance of central 
nervous system (CNS) dysfunction, yet no effective therapy exists to prevent these lethal disorders 
(Prusiner 1991). In humans, sporadic and heritable forms of the disease occur much more frequently 
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than the infectious forms (Colby and Prusiner 2011). To date, over 40 different mutations of the PrP 
gene have been shown to segregate with the heritable human prion diseases. Familial  CJD  (or FFI 
for fatal familial insomnia according to the clinical symptoms) and  GSS  are genetic  disorders. 
The first description of GSS was in a large Austrian family  with  affected  members manifesting  
slowly  progressive cerebellar ataxia admixed with cognitive decline at some time in the course of 
their illness. A variety of mutations in PRNP gene have been associated with this disorder. Some of 
these are a missense mutation at codon 198 (Dlouhy et al. 1992), a tyrosine to stop mutation at 
codon 145 (Kitamoto et al. 1993), a proline to leucine mutation at codon 105 (Kitamoto et al 1993b) 
and a 144 base pair insertion (Poulter et al. 1992). However, the most common mutation is a proline 
to leucine mutation at codon 102 (Hsiao et al. 1989). Symptoms usually begin in the fifth or sixth 
decade, but the onset may be as young as 25 years and they include combinations of cerebellar and 
pyramidal dysfunction, behavioural difficulties, and cognitive decline (Brown et al. 1991).  
The sleep disruption, characterized  by  prominent  nocturnal  insomnia, constitutes  the  salient  
clinical  hallmark  of  FFI. The term was first used in 1986 to depict an illness afflicting five 
members of a large Italian family  but it was not until  1992  that  the  disorder  was  proposed  as  a  
novel, genetically determined prion disease (Medori et al. 1992). As in the case of GSS, several 
different mutations has been discovered to cause FFI. Two of these are  a  PrP  gene  point  
mutation at codon 200, resulting in a glutamic acid to lysine substitution (Hsiao et al. 1991), and  a 
GAC to AAC mutation at codon 178 of the gene, causing substitution of asparagine for aspartic 
acid (D178N) (Goldfarb  et al. 1991).  
Sporadic Cruetzfeldt-Jacob disease accounts for 85% of all CJD cases with annual worldwide 
incidence of 1-2 cases/million population. Clinical symptoms include rapidly progressive dementia, 
cerebellar dysfunction including muscle incoordination, and visual, speech and gait abnormalities. 
Dementia is the major symptom followed by spontaneous or induced myoclonia. During the disease 
course, symptoms of pyramidal and extrapyramidal dysfunction with reflexes, tremors, spasticity 
and rigidity, and behavioral changes with agitation, confusion and depression may also be observed. 
At the end of the disease course, most of patients go into a state of akinetic mutism (they become 
unresponsive to exterior stimuli) (Belay 1999). The clinic-pathological and molecular phenotypes of 
sCJD are greatly influenced by variations in PRNP. PRNP polymorphisms, like M129V or E219K 
(Palmer et al. 1991, Shibuya et al. 1998) as well as coding sequences have been associated with 
predisposition to the disease development. 
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Infectious forms of human prion diseases account for only 5% of cases of human prion diseases 
(Muhammad et al. 2011). They include kuru, iatrogenic CJD and a new variant form of CJD. 
Kuru has occurred exclusively in the Fore linguistic group of Papua New Guinea Eastern Highlands  
and the neighboring peoples with whom they intermarried. There was a practice among these 
groups to consume the dead bodies of their relatives as a mark of respect and mourning (ritualistic 
cannibalism). Women and young children of both sexes were more exposed to the risk material 
such as brain and viscera than adult men who usually had preferentially to consume muscles. The 
kuru epidemic killed 1-2% of the population at its peak. With a ban on ritualistic cannibalism in the 
mid 1950s imposed by Australian authorities, the incidence of the disease started to decline steadily 
(Glasse 1967). Cerebellar ataxia, tremors and choreiform and athetoid movements are distinctive 
and prominent clinical signs. 
Iatrogenic CJD (iCJD) was first described in 1974 in a person who received cadaveric corneal 
transplant from a patient of CJD (Duffy et al. 1974). Several cases of human prion disease, since 
then, have been associated with iatrogenic transmission of CJD due to intramuscular injections of 
contaminated cadaveric pituitary-derived human growth hormone (hGH) and gonadotrophin 
hormone or  transplants  of  corneas  obtained from  people  who  died  of  CJD. 
vCJD results from prions being transmitted from cattle with bovine spongiform encephalopathy 
(BSE, or “mad cow” disease) to humans  through  consumption  of  contaminated beef products. 
 
In addition to the three prion diseases of humans, four disorders of animals are included in the 
ensemble of prion diseases: scrapie of sheeps  and goats (the  most  studied of  the prion  diseases), 
bovine spongiform encephalopathy (BSE),  transmissible mink encephalopathy and chronic wasting 
disease. Unlike in humans, prion diseases in animals mainly occur as infectious disorders. As in 
humans, prion disease in animals is characterized by neuropathologic changes, including 
vacuolation, astrocytic gliosis, and PrP deposition. Bovine spongiform encephalopathy,  
transmissible mink encephalopathy and chronic wasting disease are all thought  to  result from  the  
ingestion  of  scrapie-infected animal products. 
 
The prion protein and its interaction partners (aim of the thesis) 
The identification of binding partners of the prion protein has always captured the attention of many 
research groups. The interest in finding PrP ligands is on one way due to the identification of the 
protein X, believed to be a necessary component of the pathogenic conformational conversion; on 
the other way it relies to the fact that PrP might not have an intrinsic physiological activity, but can 
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modifies the function of other proteins interacting with them. As a GPI-anchored protein, PrP was 
found to interact with some extracellular or plasma membrane proteins such as apolipoprotein, 
laminin, GAGs, caveolin-1, tyrosine kinase fyn (Vana et al. 2007 for review). It has also been 
proved that PrP can bind nucleic acid (Nandi 1997). Finally, PrP can interact with numerous 
intracellular proteins, most of them located in the cytosol. Among them we can find synapsin-1b, 
neuroglobin, 14-3-3 protein, tubulin and mahogunin (Nieznanski 2010 for review). 
Even if the topological localization of PrP on the plasma membrane suggests that most of its 
binding partners are extracellular or membrane-associated, there are increasing evidences that the 
identification of new intracellular interaction partners of the prion protein may be useful to 
understand both the physiological role of the protein and the mechanism involved in 
neurodegeneration.  
PrP is located in the cytosol in subpopulations of neurons in the hippocampus, neocortex, and 
thalamus. Cytosolic PrP may have altered susceptibility to aggregation, suggesting that these 
neurons might play a significant role in the pathogenesis of prion diseases (Mironov et al. 2003). 
Other studies have suggest that in TSE PrP
SC
 inhibits the proteasome leading to the accumulation of 
cytosolic PrP (Kristiansen et al. 2007) and that accumulation of even small amounts of cytosolic 
PrP are strongly neurotoxic in cultured cells and transgenic mice (Ma et al. 2002). Hence, 
particularly at  pathologic  conditions,  intracellular  proteins  may be exposed to interactions with 
PrP. It is also plausible that at its normal, low concentration in the cytoplasm PrP may modulate the 
physiological functions of the interacting proteins whereas at elevated, pathological levels it may 
dysregulate them leading to neurodegeneration (Nieznanski 2010). Moreover, some  physiological   
interactions with intracellular proteins may be related to biogenesis/modifications of PrP and 
trafficking of PrP within  the  cell and therefore they may control PrP expression, localization and 
activity.  
In this contest, we tried to find out neurologically relevant PrP binding partner conscious that the 
identification of PrP interactors or inhibitors of interaction can help us to better understand the role 
of the prion protein in physiological and pathological condition, but also that they may be 
considered as potential target for drugs. 
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Tyrosine hydroxylase 
Tyrosine hydroxylase (also known as tyrosine 3-monooxygenase) is an enzyme that catalyses the 
conversion of L-tyrosine to L-dopa, which is the first, rate-limiting step in the biosynthesis of 
catecholamines dopamine, noradrenaline and adrenaline, important as  hormones and 
neurotransmitters in both the central and peripheral nervous systems, where they are  synthesized in 
the adrenal medulla. Catecholamine neurotransmitters in the brain regulate a wide range of brain 
function, such as movement, cognition, learning, emotion, memory, biorhythm, reproduction and 
endocrine function by acting across synapses through dopamine receptors and α- and β- adrenaline 
receptors of the neuronal network. In peripheral tissue, noradrenergic sympathetic neurons secrete 
noradrenaline as a neurotransmitter from their nerve endings. The adrenomedullary cells secrete 
adrenaline as hormones which regulate various functions such as stress reactions, blood pressure, 
blood glucose level and blood circulation, by acting on cells with α- and β- adrenaline receptors. 
Deficits and surfeits in the levels of catecholamines have many repercussions and are involved in 
many diseases including neuropsychiatric diseases (Parkinson’s disease and schizophrenia), 
cardiovascular diseases (hypertension and cardiac diseases) and metabolic diseases (diabetes 
mellitus). All these functions and involvements into several diseases make tyrosine hydroxylase an 
enzyme of great interest in many fields of biomedical research (Nagatsu 1995, Daubner et al. 2011).  
 
The TH reaction 
Together with phenylalanine hydroxylase and tryptophan hydroxylase, tyrosine hydroxylase 
belongs to the family of aromatic amino acids hydroxylases (AAAHs), a group of iron-containing, 
biopterin-dependent amino acid hydroxylases. All three hydroxylases are rate-limiting catalysts that 
use tetrahydrobiopterin (BH4) and O2 to hydroxylate their respective aromatic amino acid substrates 
(Fitzpatrick 1999). The hydroxylation in the META position of L-tyrosine to DOPA is catalyzed by 
TH together with BH4, O2 and Fe
2+
. In the reaction, the cofactor 5,6,7,8-tetrahydrobiopterin (BH4) 
is converted into tetrahydrobiopterin-4a-carbinolamine (4a-BH4). Under physiological conditions, 
4a-BH4 is dehydrated to quinonoid-dihydrobiopterin (q-BH2) by the enzyme pterin-4a-
carbinolamine dehydratase (PCD) and a water molecule is released in this reaction. Then, the 
NAD(P)H dependent enzyme dihydropteridine reductase (DHPR) converts q-BH2 back to BH4 
(Teigen et al. 2007). The Fe
2+
 is bound to TH and is able to be oxidized to Fe
3+
 by O2 and when this 
reaction occurs, the enzyme is inactivated (Ramsey et al. 1996).  
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Fig: 8. BH4 pathway and involvement in the biosynthesis of catecholamines (Nagatsu 1995). 
TH is subject to two types of feedback inhibition by the catechols. Firstly, TH activity is inhibited 
by the ability of all of the catechols to compete with BH4 for binding of the ferric iron at the 
catalytic site of the enzymes thus inhibiting cofactor interaction; secondly, catechols can bind 
almost irreversibly with the ferric iron at the TH catalytic site (Kumer and Vrana 1996). Loss of CA 
binding allows the Fe
3+
 to be reduced by BH4, thereby returning the enzyme to the fully active state. 
TH is also subject to inhibition by the substrate L-tyrosine and by excess BH4 (Dunkley et al. 2004). 
 
Fig: 9. Active and inactive form of tyrosine hydroxylase (Dunkley et al. 2004). 
The product of the enzymatic reaction, L-DOPA, can be transformed to dopamine by the enzyme 
DOPA decarboxylase. Dopamine may be converted into norepinephrine by the enzyme dopamine 
β-hydroxylase, which can be further modified by the enzyme phenylethanol N-methyltransferase to 
obtain epinephrine (Nagatsu et al. 1964). 
 18 
 
 
Fig: 10. Pathway of the biosynthesis of catecholamines (Nagatsu 1995). 
The TH gene 
The human TH gene is located on the short arm of chromosome 11 in band 15.5, a highly gene-rich 
region (Craig et al. 1986). In humans it consists of 14 exons, interrupted by 13 introns, spanning 
approximatively 8,5 Kb, while it has 13 exons in animals. In subprimates, a single form of tyrosine 
hydroxylase (TH) is expressed (Haycock 2002), whereas two TH protein isoforms have been 
identified in monkeys (Ichinose et al. 1993) and four isoforms have been demonstrated in humans. 
The four isoforms are produced from  a single gene by alternative mRNA splicing in the N-terminus 
(Kobayashi et al. 1988) and they differ only in the inclusion of 12, 81 or 93 base pairs sequences 
between nucleotide 90 and 91 of the human TH mRNA. There are two modes of alternative 
splicing: the alternate use of two donor sites in exon 1, whereby the selection of the two donor sites 
determines the insertion of the 12bp sequence; and the insertion of an entire exon 2 (Nagatsu 1995).  
 19 
 
 
Fig: 11. Structure of the human TH gene and schematic illustration of the pathway of alternative splicing producing four isoforms of 
mRNA and proteins (adapted from Nakashima et al. 2009). 
 
Tyrosine hydroxylase is found in the brain, gut and retina, the sympathetic nervous system and the 
adrenal medulla. The protein exists both in  cytosolic and membrane-associated forms (Kuhn et al. 
1990). The distribution of the two forms seems to be region-specific, with soluble TH 
predominating in the substantia nigra and locus  coeruleus,  while  in  nerve  endings  or  axons  the  
enzyme it seems  to  be  associated  with microtubules and membranes (Pickel et al. 1975). The 
membrane association seems to be related with the packaging of transmitter into synaptic vesicles 
(Chen et al. 2003). The binding of tyrosine hydroxylase to membranes involves the N-terminal 
region of the enzyme, and may be regulated by a three-way interaction between 14-3-3 proteins, the 
N-terminal region of tyrosine hydroxylase, and negatively charged membranes (Halskau et al. 
2009). 
The TH structure 
Tyrosine hydroxylase is a tetrameric protein of about 240KDa, each subunit having a mass of 
approximatively 60 KDa. It is constituted of 498 amino acids and is highly conserved among 
species. Tyrosine hydroxylases shares a lot of structural features with the others member of the 
aromatic amino acid hydroxylases (AAAHs) phenylalanine hydroxylase (PheH) and tryptophan 
hydroxylase (TrpH). Each enzyme has a multi-domain structure, with an amino-terminal regulatory 
domain of varying size from 100–160 amino acid residues, and a carboxyl terminal domain 
composed of  a  catalytic  domain  of  about  330  residues  and  a coiled-coil domain at the carboxyl 
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terminus of about 40 amino acids that allows the tetramerization of the protein (Vrana et al. 1994; 
Daubner et al. 2011). The catalytic core bounds iron atom, which is held in place in the active site 
cleft by two histidine residues and a glutamate residue, and it must be in the ferrous state to carry 
out catalysis. While there is a fine crystal structure of the C-terminus domain of the protein 
(Goodwill et al. 1997), the N-terminus has never been crystallized, presumably due to its flexibility 
and also attempts to  crystallize it with ligands have been unsuccessful (Daubner et al. 2011). 
 
Fig: 12. Crystal structure of human tyrosine hydroxylase catalytic domain (PDB ID: 2XSN). 
 
TH regulation 
Since tyrosine hydroxylase  catalyses the rate limiting step in the biosynthesis of catecholamines, it 
is regulated in a very complex way. In the short term, TH activity is mainly regulated by 
phophorylation of serine residues in the N-terminus regulatory domain by various protein kinases; 
in the long term, such as under stress, TH is regulated at the transcriptional level resulting in the 
induction of the enzyme.  
In the short term, TH is subject to two types of feedback inhibition by the catechols. Firstly, TH 
activity is inhibited by the ability of all of the catechols to compete with BH 4 for binding of the 
ferric iron at the catalytic site of the enzymes thus inhibiting cofactor interaction. This is a classic 
kinetic-mediated, readily reversible inhibition and acts as a sensor of the local concentrations of the 
catechols. Secondly, catechols can bind almost irreversibly with the ferric iron at the TH catalytic 
site. This decreases enzyme activity and stabilizes the enzyme (Kumer and Vrana 1996). 
Phosphorylation of TH alters the enzyme’s conformation leading to a form of TH that is still 
inhibited but one in which dissociation of bound catechols is now reversible (Ramsey and 
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Fitzpatrick 1998). Loss of catechols binding allows the Fe
3+
 to be reduced by BH4, thereby 
returning the enzyme to the fully active state. TH is subject to feedback inhibition by a range of 
catechols but the physiologically relevant catecholamines dopamine, noradrenaline and adrenaline 
all have the highest affinity. Catecholamines inhibit TH activity by competing with BH4 for the 
catalytic binding site. The effect of phosphorylation of TH is to cause a conformational change in 
TH and decrease the affinity of the bound catechols and therefore increase their rates of 
dissociation. (Ramsey and Fitzpatrick 1998; Ramsey and Fitzpatrick 2000, Dunkley et al. 2004). 
The most important short term mechanism for regulation of TH is activation by phosphorylation via 
protein kinases and deactivation by dephophorylation by protein phosphatases. Rat TH can be 
phosphorylated at serine residues (Ser) 8,  19,  31  and  40  by  a  variety  of  protein  kinases 
(Haycock and Wakade 1992). The human isoforms undergo phophorylation also at Thr8 (Grima et 
al. 1987). The regulation  of  the  phosphorylation  of  these  sites  and  the consequences  in  terms  
of  TH  activity  in  vitro  have  been extensively investigated, while in vivo mechanisms are less 
clear. Tyrosine hydroxylase can be phosphorylated at Ser40 in vitro by eight different protein 
kinases and dephosphorylated at Ser40 by two protein phosphatase. The protein kinases include  
protein kinase A (PKA), protein kinase C (PKC),  calcium-   and   calmodulin- stimulated protein 
kinase (CaMPK) II, protein  kinase  G  (PKG),  MAPK-activated  protein  kinases  (MAPKAPKs)  
1  and  2 ,  p38-regulated/activated  kinase  (PRAK) and mitogen- and stress-activated protein 
kinase (MSK) 1. Ser40 is phosphorylated mainly by PKA that is able to phosphorylate Ser40 of all 
four subunits of the enzyme molecule, causing a marked activation, whereas PKC and CaMPK 
phosphorylate only  two of the four subunits. MAPKAPK2  had  a  preference  for Ser40  and  
phosphorylated  Ser19  at  about  half  the  rate while CaMPKII and PRAK had a preference for 
Ser19.  Ser40 is dephosphorylated by protein phosphatase 2A and 2C (PP2A and PP2C).  
Ser31 is phosphorylated by the extracellular signal-regulated kinase 1 and 2 (ERK1 and ERK2), 
two microtubule associated protein kinases. The phosphorylation of TH at Ser31 is much slower 
and increased the enzyme activity to a lesser extent than that of both Ser19 and Ser40 and often 
occurs at the time when Ser19 phosphorylation is already declining. Ser31 is dephosphorylated by 
PP2A. 
TH is mainly phosphorylated at Ser19 by the CaMPKII in response to depolarizing agents and 
increases in intracellular calcium. Ser19 is also phosphorylated by MAPKAPK2 and PRAK. Ser19 
is dephosphorylated by PP2A and PP2C. 
Ser8 is phosphorylated by PDPK and can also be phosphorylated by ERK in vitro but at a ninefold 
lower rate than Ser31. The phosphorylation of TH at Ser8 has been shown to be increased by EGF 
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(Haycock 1990, Sutherland et al. 1993, Nagatsu 1995, Dunkley et al. 2004, Lehmann et al. 2006, 
Daubner et al. 2011). 
 
Fig: 13. Kinases and phosphatases acting on TH serine residues (Dunkley et al. 2004). 
 
 
In the presence of NO and superoxide TH is nitrated at three tyrosine residues with resulting loss of 
activity. Nitration may be a mode of regulation of TH activity in the cell. Oxidizing conditions also 
result in the modification of six of the seven cysteine residues of TH by thiolation.  
TH is, also, regulated by the interaction with other proteins. In 1987, Ichimura et al. found that 14-
3-3 protein, an acidic neuronal protein, activates the enzyme. Only in the presence of 14-3-3 
protein, TH is activated by phosphorylation of Ser19 (Ichimura et al. 1987). Also α-synuclein, 
shown to shares physical and functional homology with  14-3-3 protein (Ostrerova et al. 1999), can 
modulate the activity of TH. α-synuclein has been shown to bind to TH and to diminish TH   
phosphorylation   and   DOPA   production (Perez et al. 2002).  
TH can also be regulated in the long term, such as under chronic stress, by regulation of gene 
expression (enzyme stability, transcriptional  regulation,  RNA  stability,  alternative  RNA  splicing 
and  translational  regulation).  Protein kinases, that activate the enzyme in the short term, can also 
induce TH protein in the long term, having a dual regulatory role. The expression of TH can also be 
regulated in the long term by various first messengers such as dopamine, dopamine agonist and 
antagonist, angiotensin II and by PKA and PKC signal transduction pathways (Nagatsu 1995). 
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TH in diseases 
Since catecholamines are closely related to the pathogenesis of neuropsychiatric and cardiovascular 
disorders, TH has been suggested to play an important role in a number of diseases. TH seems to be 
particularly involved in the pathogenesis of Parkinson’s disease, a common neurodegenerative  
disorder that is clinically characterized by tremor, bradykinesia, rigidity, and loss of postural  
reflexes. It is believed that these symptoms are caused by a dopamine deficiency due to 
degeneration of dopaminergic neurons probably accompanied by a decrease dopamine biosynthetic 
capacity in the surviving cells. A direct pathogenic role of TH has also been suggested as the 
enzyme is a source of reactive oxygen species (ROS). These compounds can cause oxidative 
damage to cellular macromolecules (lipids, protein, nucleic acids and carbohydrates) leading to 
cellular death (Haavik and Toska 1998). TH expression and activity have also been related to 
mental diseases, especially bipolar affective disorders and schizophrenia. To better understand TH 
alteration consequences, genetically modified mice carrying targeted mutation in the TH gene were 
generated. Knockout mice lacking the TH gene (homozygous mutation) die at a late stage of 
embryonic development or soon after birth. Lack of TH activity in these  mice  causes  severe  
depletion  of dopamine,  noradrenaline, and adrenaline in tissues. These changes do not affect gross 
development of the cells that normally produce catecholamines. However,  surviving  newborn 
mutants  display  abnormal  electrocardiograms  characterized by reduced heart rate and prolonged 
P–Q interval, suggesting alterations in cardiovascular function in the mutant mice. Knockout of TH 
function causes perinatal   lethality   probably   because   of   cardiovascular failure (Kobayashi et 
al. 1995, Zhou et al. 1995, Kobayashi and Nagatsu 2005).  
Mice heterozygous for the TH mutation show a reduced TH activity in the tissues (approximately 
40% of the wild type), although they are apparently normal in development and gross behavior. In 
these mice, noradrenaline accumulation in the brain regions is moderately reduced to 73–80%  of 
the  wild  type levels and the reduction in TH activity causes  defects  in  some  neuropsychological 
functions at least associated with noradrenaline transmission in the brain (Kobayashi et al. 2000). 
Mutations in the human TH gene have been reported in some inherited neurological diseases. 
Lüdecke et al. identified a point mutation in exon 11 of the tyrosine hydroxylase gene, resulting in 
an amino acid exchange of Gln381 to Lys381, in a Segawa's syndrome affected family (Lüdecke et 
al. 1995). When expressed by a coupled in vitro transcription-translation system and in E.coli, the 
mutant enzyme represents a kinetic variant form, with a reduced affinity for L-tyrosine. The 
'residual activity' of about 15% of the corresponding wild-type hTH is compatible with the clinical 
phenotype of the two Q381K homozygote patients carrying this recessively inherited mutation 
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(Knappskog et al. 1995). Another mutation in the tyrosine hydroxylase gene was found in three 
patients originating from three unrelated Dutch families with autosomal recessive L-DOPA-
responsive dystonia (DRD). An A698G transition in the exon six resulted in the substitution of the 
evolutionary conserved arginine 233 by a histidine (R233H) (Van den Heuvel et al. 1998). 
Moreover, a deletion of a single nucleotide C at the nucleotide 291 in the exon three, that generates 
a truncated  form  of  TH  protein,  was  identified  in  the  patient who  is  compound   heterozygous   
for  this   mutation and the mutation A to G at the nucleotide 698 (Wevers et al. 1999). Lüdecke et 
al. also identified a T614C transition in exon 5 resulting in a leucine to proline transition (L205P) in 
a girl presenting parkinsonian symptoms in early infancy and a very low level of the dopamine 
metabolite homovanillic acid in the CSF. The recombinant mutant enzyme had a low homospecific 
activity, approximately 1.5% of wilde type hTH in E.coli and approximately 16% in a cell-free in 
vitro transcription-translation system (Lüdecke et al. 1996). 
All these data together seems to indicate TH as a potential molecular target for the treatment of 
catecholamines-related diseases. Cell transplantation or gene terapy may restore the TH activity, 
compensating for decreased levels of catecholamines in neurological and cardiovascular diseases, 
for example, for supplementation of dopamine in Parkinson’s diseases. 
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HSPB8 
A living cell responds to the different environmental stresses such as increased temperatures, pH 
extremes, osmotic pressure variation, hypoxia and noxious chemicals, by selectively inducing or 
overexpressing genes that code for protective proteins called HSPs (heat-shock proteins). HSFs 
(heat-shock factors) bind to HSEs (heat-shock elements) upstream of the HSP genes and bring 
about their increased expression, conferring tolerance to stress (Chowdary et al. 2004). Under stress 
conditions or as a result of genetic mutations, proteins tend to expose hydrophobic regions which 
are normally buried inside the molecule and become unstable. As a consequence of these novel 
acquired biophysical properties, these proteins will interact with each other through their 
hydrophobic regions, leading to protein aggregation which can also lead to the formation of highly 
ordered fibrillar aggregate called amyloid (Hartl et al. 2009, Hartl et al 2011, Carra et al. 2012).  In 
such conditions, HSPs play a fundamental role acting as molecular chaperones. They recognize and 
bind to misfolded proteins and participate in either their refolding or, alternatively, assist their 
degradation via the major degradative systems (ubiquitine/proteosome and autophagy) (Carra et al. 
2012). The modern classification of the human heat shock proteins, based on their molecular 
masses, contains the following main groups: HSPH (former name HSP110), HSPC (HSP90), HSPA 
(HSP70), HSPD/E (HSP60/HSP10) and CCT (TRiC), DNAJ (HSP40), and HSPB (small HSP) 
(Mymrikov et al. 2011, Vos et al. 2008).  
 
 
Fig: 14. Conditions that induce heat shock response (Morimoto 1998). 
  
sHSPs perform many physiological functions including the maintenance of the cellular 
cytoskeleton, the regulation of protein aggregation and the modulation of cell survival in a number 
of cell types including glial and neuronal cells (Quraishe et al. 2008). The members of this family 
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share some important features: they form the conserved structure 'alpha-crystallin domain' with 
about 80-100 residues in the C-terminal part of the proteins; they have monomeric molecular 
masses ranging in 12-43 kDa; they associate into large oligomers consisting in many cases of 
subunits; they increase expression under stress conditions; they exhibit a highly dynamic structure 
and they play a chaperone-like role. Ten mammalian sHSPs have been identified so far (HSPB1-
HSPB10), of which αβ-crystallin, HSP20 and HSP27 are the most extensively studied (Hu et al. 
2007).  
 
Fig: 15. Structural domains of HSP27, HSP22 and αB-crystallin human proteins (Acunzo et al. 2012). 
 
Among them, HSPB8 (also named HSP22, H11, E2IG1) is of special interest because it seems to 
have an important role in a series of physiological and pathological process and because mutations 
in its sequence (K141E and K141N) correlate with the development of distal motor neuropathy type 
II and Charcot-Marie-Tooth disease type 2 (Irobi et al. 2004b, Tang et al. 2005). Moreover, recent 
studies showed that HSPB8 is trapped within inclusions formed by proteins with polyglutamine 
tails and is able to prevent formation of aggregates formed by this protein. HSPB8 was detected in 
senile plaques and cerebral amyloid angiopathy which are pathological lesions of Alzheimer's 
disease and hereditary cerebral hemorrhage with amyloidosis of the Dutch type (Carra et al. 2005, 
Wilhelmus et al. 2006, Wilhelmus et al. 2009). All these data together seem to suggest a protective 
role in the cell both by preventing aggregation and/or promoting degradation of improperly folded 
proteins and make HSPB8 a very promising target for understanding and cure neurodegenerative 
disease.  
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Different names of the HSPB8 
The different names attributed to HSPB8 derive from independent works which describe novel-
identified genes, subsequently found to have the same sequence.  
Smith et al. reported the isolation and characterization of a novel gene, designated H11, that 
contains an open reading frame of 588 nucleotides, which encodes a protein similar to ICP10, the  
large subunit of herpes simplex virus type 2 ribonucleotide reductase which is a multifunctional 
protein that contains a serine-threonine protein kinase (PK) activity (Smith et al. 2000b). The H11 
gene maps at  chromosome site 12q24.1-12q24.31 (Yu et al 2001) and consists of 1835bp. A search 
for heat-shock elements revealed two heat-shock factor–binding sites upstream of ATG of the gene 
(Chowdary et al. 2004). The gene  encodes a protein of 196 amino acids with a calculated molecular 
weight of 21.6 kDa. The protein shared a 40% identity to the small heat shock protein HSP27 
(Aurelian et al. 2001). In the same year Charpentier et al. cloned five novel genes (E2IG1-5), which 
were observed up-regulated by hormonal treatment. Of these the most highly induced transcript, 
E2IG1, appeared to be a novel member of the family of small heat shock proteins, showing a 54% 
homology to HSP27 (Charpentier et al. 2000). In 2001 Benndorf et al performed a yeast two-hybrid 
screen of a human heart cDNA library for HSP27-interacting proteins. In this way they identified a 
protein with a molecular mass of 21.6 kDa containing the α-crystallin domain in its C-terminal half, 
a hallmark of the superfamily of small stress proteins. Thus, the new protein itself was considered a 
member of this protein superfamily, and consequently designated as HSP22 (Benndorf et al. 2001). 
Being the eighth known human sHSP it was named also HSPB8 (Kappé et al. 2001).  
HSPB8 in Drosophila 
In a review by Hu et al. HSPB8 gene is related to the Drosophila melanogaster HSP22 gene (Hu et 
al. 2007). The HSP22 gene was first described in 1980 by Craig and McCarthy which isolated a 
11Kb region of the 67B locus of the Drosophila melanogaster genome including the 27K, 26k, 23K 
and 22K heat shock proteins. The DmHSP22 gene is approximately 1.1Kb in length and the RNAs 
encoding the heat shock proteins are transcribed from the same DNA strand (Craig and McCarthy 
1980). Each of the four genes contains on their 5’ flanking regions an A-T rich sequence, either 
TATAAATA or TATAAAAG, which is flanked by a G-C rich region. This A-T rich sequence ends 
about 23bp upstream from the proposed site of initiation of transcription. This sequence is also 
found in the gene for the major heat shock protein, HSP70 (Ingolia and Craig 1981). The gene 
encoding HSP22 has three heat shock element (HSE) upstream of the transcribed region and two of 
them are closely spaced and only 26 and 46bp from the TATA box (Klemenz  and Gehring 1986). 
DmHSP22 was found to localize in the mitochondrial matrix where it tends to form  oligomers in 
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vivo and it was shown to be a key player in cell-protection mechanisms against oxidative injuries 
and aging, playing a positive role in lifespan determination (Morrow et al. 2000,Morrow et al. 
2004a-b, Tao et al. 2004, Wadhwa et al. 2010, Chen  et al. 2011). Immunoprecipitation results 
indicate that there is no interaction between DmHSP22 and the other small heat shock proteins 
(Morrow et al. 2000). Moreover, it was shown that DmHSP22 expression in human cancer cells 
increased their malignant properties including anchorage-independent growth, tumor formation in 
nude mice, and resistance to a variety of anticancer drugs interacting and inactivating wild type 
tumor suppressor protein p53 (Wadhwa et al. 2010) 
This direct relation between mammalian and Drosophila melanogaster HSP22 was, however,  
argued by Shemetov et al. in a more recent review. The authors sustain that it is inappropriate to 
directly compare DmHSP22 with mammalian HSP22 in the absence of a detailed phylogenetic 
analysis. A BLASTP structural comparison between human HSP22 and four sHSP of Drosophila 
(DmHSP22, DmHSP23, DmHSP26, DmHSP27), indeed, revealed that human HSP22 is more 
similar to DmHSP27 than to DmHSP22 (Shemetov et al. 2008b).  
In 2010 Carra et al. finally suggested the Drosophila melanogaster HSP67Bc (Dm-HSP67Bc) as the 
closest  ortholog of human HSPB8 on the basis of a functional analysis. Dm-HSP67Bc is, like 
human HSPB8, able to induces autophagy via the eIF2α pathway and has the in vitro potential to 
protect against mutated ataxin-3-mediated toxicity and decrease the aggregation of a mutated form 
of HSPB1 (P182L-HSPB1) associated with peripheral neuropathy (Carra et al. 2010). 
 
Tissue distribution and cellular localization 
Lots of laboratories focused their attention on the tissue distribution of HSPB8. 
Verschuure et al. studied expression of sHSP  in porcine lens, brain, heart, liver, kidney, lung, 
skeletal muscle, stomach, and colon, and found a ubiquitous expression of  HSPB8. During 
development, the sHSPs tend to temporarily increase in stomach, liver, lung, kidney, hippocampus, 
and striatum, while expression in heart is more or less constant, and a large variation is found in 
sHSP expression patterns in skeletal muscle. In cerebellum and cortex a temporary decrease of 
HSP20 and HSPB8 is observed directly after birth (Verschuure et al. 2003). 
Analysis of abundance of human HSP22 mRNA (Northern blotting) reveals a single signal in 
several tissues with a size of ∼1.8 kilobase pairs. The highest expression of hHSP22 was found in 
skeletal and smooth muscles, heart, and brain. Expression was moderate in cervix, prostate, lung, 
and kidneys, whereas virtually no signal was seen in ovaries, testis, liver, pancreas, spleen and 
blood  (Benndorf et al. 2001, Kappé et al. 2001).  
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The HSP22 expression in the brain has been intensively investigated. Quraishe et al. analyzed its 
expression in mouse brain by reverse-transcriptase polymerase chain reaction (RT-PCR), in situ 
hybridization and Western blotting. The results demonstrate a ubiquitous expression of HSPB8 
involving the dorsal 3rd (d3v) and later ventricles (lv) of the brain, but also the synaptosomal 
fraction (Quraishe et al. 2008). Using in situ hybridization and quantitative real-time RT-PCR, 
Kirbach et al. showed HSPB8 to be expressed in all rat brain regions. The expression is low in 
embryonic and postnatal hippocampus while increase significantly in adult hippocampus. Heat 
shock in cultured hippocampal neurons lead to a significant induction of HSPB1 and HSPB8 but not 
of the other sHSPs (Kirbach  et al. 2011). 
In a recent work  Ramìrez-Rodrìguez and colleagues found that expression of HSPB8 increases 
during differentiation in vitro and is particularly associated with later stages (48-96 h) of 
differentiation. In the dentate gyrus of adult mice in vivo, lentiviral overexpression of HSPB8 
doubles the surviving cells and concomitantly promotes differentiation and net neurogenesis 
without affecting precursor cell proliferation through a mechanism involving the α-crystallin 
domain of the protein (Ramírez-Rodríguez et al. 2013). 
All these data suggest that HSPB8 might be a very important modulator of brain growth, being 
involved in both neuron cell cycle and neuroprotection under stress conditions. 
The cellular localization of HSPB8 is, to date, not well characterized. The data of size-exclusion 
chromatography of extracts of estrogen receptor-positive breast cancer cells indicate that HSPB8 is 
detected predominantly in cytoplasm and is eluted in the fractions containing proteins with apparent 
molecular masses in the range of 30–670 kDa (Sun et al. 2007). However, other studies indicate that 
it may interact with the membrane or proteins associated with the inner surface of the membrane 
(Yu et al. 2001). Immunolocalization studies in a human neuroblastoma cell line, SK-N-SH, using 
confocal microscopy show that a significant fraction of HSP22 is localized to the plasma 
membrane. In vitro studies show that HSP22 binds stably with lipid vesicles; the extent of binding 
depends on the nature of the lipid. HSP22 binds more strongly to vesicles made of lipids containing 
a phosphatidic acid, phosphatidylinositol or phosphatidylserine headgroup (known to be present in 
the inner leaflet of plasma membrane) compared with lipid vesicles made of a phosphatidylcholine 
head-group alone and this binding can lead to conformational changes of the protein suggesting an 
important role of the interaction in the cellular function of the protein (Chowdary  et al. 2007).  
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HSPB8 physicochemical properties and interaction with sHSPs and other ligands 
Up to now all attempts to obtain structural data of full size mammalian sHSP were predominantly 
unsuccessful, and most investigations were performed on isolated crystallin domains of these 
proteins (Kasakov et al. 2007, Datskevich et al. 2012b). 
HSP22 was categorized as a sHSP based on the presence of the conserved α-crystallin domain in 
this protein. In HSP22, the N-terminal domain extends from residues 1–85 while the α-crystallin 
domain comprises residues 86–176. The calculated mass of HSP22 is 21.6KDa. It has an acidic pI 
of 4.9 and it is more stable at pH 8.0 than at neutral pH (Benndorf et al. 2001, Chowdary et al. 
2004, Hu et al. 2007). 
The far-UV CD spectra and predictions of secondary structure indicate that the protein belongs to 
the group of the so-called “intrinsically disordered proteins” and this is one of the reasons for its 
unusual high thermal stability. The protein contains very small quantities of α-helices (5%) and is 
enriched in unordered structure (58%) and β-strands (36%). According to the predictions, residues 
153–155 of HSP22 tend to form a α-helix, whereas residues 156 and 157 tend to form a short β-
strand that might correspond to the β8 strand of the other sHSP (Chowdary et al. 2004, Kim et al. 
2004b, Chowdary et al. 2007, Kasakov et al. 2007, Kasakov et al. 2009). The sequence of HSP22 
shows the presence of three cysteine residues not being involved in any disulphide bond, according 
with the fact that the occurrence of disulphide bonds in the HSPs is very rare (Chowdary et al. 
2004).  
The available literature indicates that HSP22 is highly susceptible to proteolysis (Benndorf et al. 
2001, Chowdary et al. 2004, Kim et al. 2006).  
 
The data on oligomeric structure of HSPB8 remain controversial. 
Quaternary structure analyses by glycerol density-gradient centrifugation and gel filtration 
chromatography showed that HSP22 exists as a monomer in vitro, unlike other members of the 
sHSP family (Chowdary et al. 2004). However, most studies do not agree with this view. Two-
dimensional gels of cell extracts showed signals  at an apparent molecular mass of ∼50 kDa 
indicating the existence of hHSP22 dimers similar to what has been described for other sHSPs such 
as hHSP27 (Benndorf et al. 2001). If the cell extract is subjected to glycerol gradient 
ultracentrifugation, HSPB8 sediments as a dimer (or even as a tetramer) (Chávez Zobel et al. 2003). 
Data from size exclusion chromatography and chemical crosslinking with dimethylsuberimidate 
indicate that HSP22 forms stable dimers (Kim et al. 2004b, Kim et al. 2006), while yeast two-
hybrid assays showed that HSPB8 not only forms dimmers but also high-order oligomers and that 
HSP22 homo-dimers are formed through N-N and N-C interactions (Sun et al. 2004). More recent 
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works suggested that wild type HSPB8 forms a mixture of monomers and dimers depending on 
concentration (Kasakov et al. 2007, Datskevich et al. 2012a) and that rat HSPB8 exists in a dynamic 
equilibrium between various oligomers mainly forming tetramer in physiological condition (pH 7.4) 
or octamers in non physiological solution (Yang et al. 2012). 
Benndorf et al. firstly described, performing yeast two hybrid system screen, HSPB8 as a 
interaction partner of a triple aspartate mutant of HSP27 (Benndorf et al. 2001). Since then, 
numerous studies have focused on possible interaction between HSPB8 and other members of the 
small heat shock proteins family. Using various techniques Sun and colleagues showed that HSP22 
interacts not only with itself, but also with cvHSP (HSPB7), MKBP (HSPB2) and HSP27.  HSP22-
cvHSP hetero-dimers are formed through C-C interaction while HSP22-MKBP and HSP22-HSP27 
hetero-dimers involve the N and C termini of HSP22 and HSP27, respectively, but appear to require 
full-length protein as a binding partner (Sun et al. 2004). Subsequently it was shown that HSP can 
interact also with HSPB6, αβ-crystallin and HSPB3 and (Fontaine et al. 2005, Fontaine et al. 2006, 
Mymrikov et al. 2012) even if some studies report that HSPB8 fail to interact with HSPB3 and 
HSPB1 (Fontaine et al. 2005, Datskevich et al. 2012a). It is possible that the creation of a binding 
between the proteins and its strength depends on the techniques and the condition used to study the 
interaction. 
 
Several factors or modifications can affect the physicochemical properties of the protein. Mutations 
associated with the development of neuropathies, for instance, can modulate HSP22 homo- and 
hetero-oligomerization. These mutations do not dramatically affect the quaternary structure but, at 
the same time, induce destabilization of the overall structure of the sHSP (Kim et al. 2006, Kasakov 
et al. 2007). The data suggest aberrantly increased interactions of mutant HSP22 forms with 
themselves, αB-crystallin and HSP27. It seems  that each mutant form of HSP22 has a characteristic 
pattern of abnormal interaction properties. Increased interactions involving mutant sHSPs may be 
the molecular basis for their increased tendency to form cytoplasmic protein aggregates, and for the 
occurrence of the associated neuropathies (Fontaine et al. 2006). Yeast two hybrid assay and 
intracellular FRET showed that the interaction of neuropathies-associated HSPB8 mutants with 
HSPB5 is stronger than the interaction of the wild-type protein with HSPB5 (Datskevich et al. 
2012a). Moreover, Kasakov et al. revealed that mutation K137E and especially a double mutant 
K137,141E lead to an increase in unordered structure in HSP22 and increase susceptibility to 
trypsinolysis. Both mutations decrease the probability of dissociation of small oligomers of HSP22 
and mutation K137E increase the probability of HSP22 crosslinking (Kasakov et al. 2007). Another 
study using phosphomimicking mutant showed that phosphomimicking mutation affect the tertiary 
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structure of the protein, promote concentration-dependent association of HSPB8 subunits and 
protect the protein from proteolysis (Shemetov et al. 2011). It has also been suggested that mild 
oxidation may increase the portion of unordered structure in the protein (Sun et al. 2004). 
 
HSPB8 has been shown to interact not only with other members of the small heat shock proteins 
family, but also with a discrete number of other proteins. For instance, using two hybrid screen, 
HSP22 was found to interact with the RNA helicase Ddx20, a component of the survival-of-motor-
neurons complex (SMN complex) involved in spliceosome assembly and pre-mRNA processing. 
Neuropathies-associated mutations have increased interaction stoichiometry with Ddx20, 
suggesting a potential role of HSPB8 in ribonucleoprotein processing (Sun et al. 2010). An 
exhaustive review by Arrigo et al. (Arrigo et al. 2013) reports all the known binding partner of 
HSP22, most of which are involved in the HSPB8 mechanisms of action (regulators of authophagy, 
protein aggregation and apoptosis regulators) related to neurodegenerative diseases and other 
diseases. 
 
HSPB8 kinase activity and phosphorilation 
Smith et al. were the first to describe the autophosphorylation activity of HSP22. Recombinant 
fusion GST-HSP22 purified from bacteria as well as immunocomplexes of HSP22 obtained from 
human cells possess autophosphorylating activity. The H11 protein has Mn
2+ 
dependent serine-
threonine-specific PK activity and it has been shown that mutation of Lys-113 located in the 
presumptive ATP-binding site results in complete ablation of autophosphorylation activity, whereas 
mutation of Lys-115 located outside of putative conservative protein kinase domains had no effect 
on the autophosphorylation of HSP22 (Smith et al. 2000b). Further experiment by Kim et al. 
showed using two different protein substrates (α-casein and histone IIIS), that HSP22 has very low 
or no kinase activity and that the activity recorded by Smith et al. was due to the presence of trace 
amounts of exogenous protein kinases contaminating immunocomplexes used in the experiments 
(Kim et al. 2004b). These finding were argued by Gober and colleagues that criticized the absence 
of a negative control (a protein that is known to lack kinase activity) and the lack of a construct  
mutated in the invariant lysine required for ATP binding (catalytic domain II). They indeed 
sustained that the data presented by Kim at al. together with the result showed by Chowdary et al., 
which evidenced that HSP22 can phosphorylate myelin basic protein (Chowdary et al. 2004), can 
prove the specificity of HSP22 kinase activity  (Gober et al. 2004). 
In a later work Kim and colleagues suggested that HSP22 contains only seven out of 11 motifs 
characteristic to protein kinases and even these seven motifs are not completely preserved. 
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Therefore, it is difficult to expect that isolated HSP22 will possess significant protein kinase activity 
(Kim et al. 2004a). 
Anyway, the autokinase/kinase activity of HSP22 is still under investigation and it is not possible to 
surely state which of the two way of thinking is the right one. 
 
Belonging to the group of intrinsically disordered proteins, HSPB8 seems to be a good substrate for 
different protein kinases (Mymrikov et al. 2011). In vitro, HSP22 is phosphorylated by protein 
kinase C (at residues Ser
14
 and Thr
63
), by p44 mitogen-activated protein kinase (ERK1) (at residues 
Ser
27
 and Thr
87
) and by casein kinase 2 but not by MAPKAPK-2 (Benndorf et al. 2001). Other in 
vitro experiments revealed that HSP22 is effectively phosphorylated by cAMP-dependent protein 
kinase and that Ser
57
 is the primary site of phosphorylation. Mutations S57D or S24,57D prevent 
phosphorylation of HSP22 and result in changes of the local environment of tryptophan residues 
and increase HSP22 susceptibility to chymotrypsinolysis (Shemetov et al. 2008a). 
Modern proteomic methods provide important information on HSPB8 phosphorylation in vivo. 
Recently published data indicate that HSPB8 is phosphorylated at Ser
24
 (Cantin et al. 2008, 
Dephoure et al. 2008) and Ser(Thr)
87 
(Villén et al. 2007). In addition, Tyr
118
 of HSPB8 was found to 
be phosphorylated in non-small-cell lung cancer cells (Rikova et al. 2007). Phosphomimicking 
mutants experiments showed that mutation S159D does not affect phosphorylation, whereas 
mutations S24D and S27D equally moderately inhibit phosphorylation and mutation T87D strongly 
inhibit phosphorylation of HSPB8. The double mutations S24D/T87D and S27D/T87D induce very 
strong inhibitory effect and the triple mutations S24D/S27D/T87D completely prevente 
phosphorylation catalyzed by ERK1. Phosphorylation promotes concentration-dependent 
association of HSPB8 subunits and affects the structure and chaperone-like activity of HSPB8 
(Shemetov et al. 2011). 
 
HSPB8 chaperone activity  
Like the other members of the small heat shock protein, HSPB8 prevents aggregation of partially 
unfolded or denatured proteins in vitro. HSP22 was found to decrease heat-induced aggregation of 
citrate synthase, to retard or completely prevent aggregation of yeast alcohol dehydrogenase (ADH) 
and heat-induced aggregation of bovine liver rhodanese, and to prevent dithiothreitol-induced 
aggregation of insulin (Morrow et al. 2006, Sun et al. 2004, Chowdary et al. 2004). The chaperone-
like activity is temperature and concentration dependent (Chowdary et al. 2004, Benndorf et al. 
2001, Sun et al. 2004). Neuropathies-associated mutations have lower chaperone-like activity than 
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the wild type protein and the chaperone activity can also be influenced by  phosphomimiking 
mutations and phosphorilation (Kasakov et al. 2007, Shemetov et al. 2011).  
The most important and innovative results, anyway, are linked to the in vivo ability to prevent or 
decrease the accumulation of misfolded protein. This peculiarity property of the HSP22 is at the 
base of a large number of  studies aimed at understanding the role of this protein in preventing 
protein aggregation, a hallmark of many neurodegenerative disorder.  
 
HSPB8 and apoptosis 
HSPB8 seems to play an important role in the regulation of apoptosis, an irreversible process 
resulting in cell death and particularly implicated in tumor growth and therapy. First results on 
HSPB8 regulation of apoptosis were a little bit controversial. Gober et al. first reported of a heat 
shock protein with proapoptotic activity. The H11 mRNA and protein levels were reduced in 
various tumor tissues and cell lines (melanoma, prostate cancer and sarcoma). In these cells, 
expression was not restored by heat shock, but rather by the demethylating agent 5-aza-2'-
deoxycytidine (Aza-C). Forced H11 expression by Aza-C treatment triggered apoptosis. A single 
site mutant (H11-W51C) had cytoprotective activity related to MEK/ERK activation, and it blocked 
H11-induced apoptosis in co-transfected and Aza-C-treated cells, indicating that it is a dominant 
negative mutant (Gober et al. 2003). However, other studies reported anti-apoptotic effects. In these 
studies the ICP10 PK domain of herpes simplex virus type two HSV-2, homologue of H11/HSPB8 
sharing with it 32% sequence identity and a number of functional properties (Aurelian et al. 2012), 
was able to protect HEK293 and PC12 cells from apoptosis activating the Ras/MEK/MAPK 
mitogenic pathway through a mechanism dependent on the protein kinase activity of the protein and 
leading to a Bag-1 upregulation (Perkins et al. 2002, Perkins et al. 2003, Smith et al. 2000a). Putting 
all these data together it seems reasonable that HSPB8 can exert both pro- and anti-apoptotic 
activity depending on the cell type (Gober et al. 2003, Shemetov et al. 2004b).  
HSPB8 in the heart 
Depre et al. firstly showed that H11 kinase gene expression is increased in a swine model of 
ischemia/reperfusion and in response to long-term pressure overload with hypertrophy, thus 
indicating possible involvement of this protein in cell survival. Adenoviral-mediated overexpression 
of H11 kinase, resulting in average 7-fold increase in  protein expression, in isolated neonatal rat 
cardiac myocytes  leads to a 37% increase in protein/DNA ratio, reflecting hypertrophy. This 
phenotype was accompanied by a dose-dependent activation of Akt/PKB and p70
S6
 kinase, whereas 
the MAP kinase pathway was unaffected. These data showed a new  mechanism by which the 
cardiac response to stress (both acute ischemia/reperfusion and chronic pressure overload) is 
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coupled to a stimulation of cell growth (Depre et al. 2001, Depre et al 2002). It was also proposed 
that H11 is a dual function kinase in cardiac rat cell: it induces hypertrophy at low doses through 
kinase-independent activation of Akt, whereas it causes apoptosis at high doses through protein 
kinase-dependent mechanisms, in particular by physical interaction  and  inhibition of CK2 (Hase et 
al. 2005). A study on metabolic adaptation to cardiac hypertrophy and ischemia revealed that H11 
promotes the synthesis of glycogen, an essential fuel for the stressed heart in both conditions of 
overload and ischemia. In transgenic mice, overexpression of H11 gene resulted in an improve 
interaction of the protein with phosphoglucomutase (PGM), the enzyme converting glucose 6-
phosphate into glucose 1-phosphate, and in 3-fold increase in the protein expression of the glucose 
transporter GLUT1 in plasma membrane, leading to an increase of glycogen content. Transgenic 
mice are characterized by increased  phosphorylation (activation) of the α-catalytic subunit of 
AMPK, he major regulator of glucose utilization in the ischemic heart (Wang et al. 2004, Depre et 
al. 2006). Experimental data on transgenic mice also evidenced that the cardioprotection conferred 
by H11K is quantitatively comparable to the protection of preconditioning, a condition in which 
short episodes of ischemia/reperfusion activate survival kinases that will protect the heart against 
myocardial infarction during subsequent ischemia. This results is achieved through two mechanism 
of cardioprotection activated downstream of phosphatidylinositol 3-kinase (PI3K): on one way 
activation of Akt promotes the phosphorylation of several downstream effectors, including GSK-3β, 
Bad, the endothelial isoform of NO synthase (eNOS), and the transcription factor Foxo. Akt inhibits 
GSK-3β, an activator of cell death and the proapoptotic effector Bad while it activates the 
cytoprotective eNOS. In the nucleus, Akt phosphorylates the proapoptotic transcription factors of 
the Foxo family, which is followed by their inhibition, and increases the expression of heat shock 
proteins. On the other way H11K activates PKCε wich triggers the expression of the inducible 
isoform of NOS (iNOS), which is particularly important in activating the delayed mechanisms of 
myocardial protection after ischemia/reperfusion (Depre et al. 2006). Thus, H11K is responsible for 
the activation of two antagonistic pathways for cell growth, the Akt pathway, which stimulates 
protein synthesis through mTOR, and the AMPK pathway, which inhibits it. TG mice are 
characterized by an increased interaction between Akt and AMPK specifically in the nucleus. Both 
the AMPK and Akt pathways stabilize the hypoxia-inducible factor-1α (HIF-1α). HIF-1α results in 
an increased expression of genes encoding enzymes regulating anaerobic metabolism and growth 
factors. It was, therefore, proposed that the subcellular translocation of AMPK and Akt to the 
nuclear periphery prevents this paradox, thereby allowing AMPK to play its cytoprotective role 
without interfering with cell growth (Danan et al. 2007). More recently studies elucidated the signal 
pathways activated by the expression of HSPB8 in cardiac cells. H11K promotes the formation of 
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the BMP receptor complex, upregulating the BMP receptors Alk3 and BMPR-II, and their ligand 
BMP4.  Activation of the BMP pathway in transgenic mice was confirmed by increased 
phosphorylation of the "canonical" BMP effectors Smad 1/5/8 leading to an increase in PI3K 
activity. H11K increased both the association of Alk3 and BMPR-II together, and their interaction 
with the transforming growth factor-beta-activated kinase (TAK)1, a "noncanonical" mediator of 
the BMP receptor signaling which mediates the activation of the PI3K/Akt pathway responsible for 
the physiological effects of H11K on cardiac cell growth and survival (Sui et al. 2009). In vitro and 
in vivo studies involving knockout mouse model deleted for HSP22 gene also demonstrate that 
HSP22 activates STAT3 via production of interleukin-6 by the transcription factor nuclear factor-
κB leading to an increase iNOS expression. The increased nitric oxide production stimulates 
oxidative phosphorylation in normoxia and decreases oxidative phosphorylation and reactive 
oxygen species production after anoxia (Chen et al. 2011, Qiu et al. 2011, Laure et al. 2012). A 
recent experiment in mouse model of infarction showed that HSPB8, at least in part, plays an 
important role in the development of the impaired mitochondrial energy-producing ability that leads 
to heart failure after a myocardial infarction (Marunouchi et al. 2013). All these data suggest HSP22 
as a potential tool for prophylactic protection of mitochondrial function during ischemia. 
Moreover, characterization of the proteasome in hearts from TG mice overespressing HSPB8 
revealed an increased expression of both 19S and 20S subunits, a doubling in 20S catalytic activity, 
a redistribution of both subunits from the cytosol to the nuclear periphery and a four-fold increase in 
nuclear-associated 20S catalytic activity (Hedhli et al. 2008). Taken together, these results 
demonstrate that H11K is responsible for the activation of a genomic program of cell survival that is 
involved in an antiapoptotic response via the Akt pathway, a preconditioning survival response by 
PKCε, a metabolic survival response via AMPK, and a growth response mediated by mTOR.  
An arg120gly (R120G) missense mutation in HSPB5 (alpha-beta-crystallin ) causes desmin-related 
cardiomyopathy (DRM), a muscle disease that is characterized by the formation of inclusion bodies, 
which can contain pre-amyloid oligomer intermediates. In vitro studies showed that HSPB8 can 
directly interrupt oligomer formation by the CryAB R120G protein.  Blockade of amyloid oligomer 
formation by HSP25 and HSP22 recovered the ubiquitin proteosomal activity and cellular viability 
(Chávez Zobel et al. 2003, Sanbe et al. 2007). These previous results were extended in vivo by oral 
administration of geranylgeranylacetone (GGA), a potent HSPs inducer, in R120G transgenic 
(R120G TG) mice. Overexpression of HSPB8 led to a reduction in amyloid oligomer and aggregate 
formation, resulting in improved cardiac function and survival (Sanbe et al. 2009).  
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HSPB8 was also shown to protect against atrial fibrillation (AF), the most common sustained and 
progressive clinical tachycardia in the population, by attenuation of the RhoA GTPase pathway at 
different levels (Ke et al. 2011). 
In in vitro studies, expression of HSPB8 K141N by adenoviral infection resulted in increased 
HSPB8-positive aggregates around nuclei and cardiac-specific HSPB8 K141N transgenic mice 
exhibited mild hypertrophy and apical fibrosis as well as slightly reduced cardiac function (Sanbe et 
al. 2013). 
All these results, confer to HSPB8 a major role in preventing and fighting a series of cardiac 
disease. Even thought additional investigations  have to be done to better understand HSP22 role in 
physiological and pathological conditions, its important role seems to be also confirmed by the fact 
that a single point mutation of HSPB8, such as K141N, can cause cardiac disease. 
HSPB8 and Immune Response 
A study by Roelofs et al. demonstrated that HSPB8 is involved in the activation of dendritic cells 
(DCs) through a mechanism dependent on its newly identified ligand toll-like receptor 4. The 
maturation of DCs induced by HSPB8 coincided with an increased production of the inflammatory 
mediators TNF-α, IL-6, IL-10, and IL-12p70. HSPB8 is abundantly expressed in synovial tissue 
from rheumatoid arthritis (RA) patients, suggesting a role during the inflammatory process in 
autoimmune diseases (Roelofs et al. 2006).  Moreover, it was found that HSPB8 induced 
interleukin-6 production in cultured pericytes and astrocytes, thus it is supposed that HSPB8 might 
be among key mediators of local inflammation associated with hereditary cerebral hemorrhage with 
amyloidosis of the Dutch type (Wilhelmus et al. 2009) 
 
HSPB8 and tumor 
HSPB8 involvement in tumors has been extensively investigated but the exact role of the protein in 
this kind of pathologies remains not easy to understand. To date, it is thought that HSPB8 has 
divergent properties in tumors, exerting both pro- or- anti-proliferative effects depending on the 
cells.   
The proliferative effect of HSPB8 was first suggested by Morrow and co-workers. They found that 
endogenous H11 RNA and protein are expressed in melanoma cell lines and primary melanoma 
tissues at levels higher than in normal melanocytes and in benign nevi, indicating that H11 
expression is associated with cell growth (Smith et al. 2000b, Yu et al. 2001). Previous studies 
showed that treatment of human breast cancer cell line MCF-7 with 17β-estradiol results in up-
regulation of the HSP22 gene (Charpentier et al. 2000). HSPB8 expression in also induced in 
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estrogen receptor-positive breast cancer cells. First, it was shown that in breast tumors induced by 
erbB2 and cyclin D1 HSPB8 displayed higher expression levels in invasive lesions than in 
preinvasive lesions using samples obtained by laser capture microdissection (LCM) from transgenic 
erbB2, ras, and cyclin D1 mice (Yang et al. 2006). Later, it was demonstrated that treatment of 
estrogen receptor-positive MCF-7 breast cancer cells with both estrogen (E2) and cadmium (Cd) is 
able to induce HSP22 showing also that in cytosolic extracts of MCF-7 cells, most of the E2- and 
Cd-induced HSP22 was incorporated into high-molecular mass complexes (Shemetov et al. 2008a). 
HSPB8 expression confers resistance to tamoxifen in breast cancer patients preventing the induction 
of autophagy and giving a proliferative advantage to the treated cells (Gonzalez-Malerva et al. 
2011, Clarke 2011). 
Despite these results, a lot of studies seem to suggest an anti-proliferative effect of the protein. 
Gober et al. showed that the H11 mRNA and protein levels were reduced in various tumor tissues 
and cell lines (melanoma, prostate cancer and sarcoma). In these cells, forced H11 expression by 
demethylating agent 5-aza-2'-deoxycytidine (Aza-C) triggered apoptosis. A single site mutant (H11-
W51C) had cytoprotective activity related to MEK/ERK activation, and it blocked H11-induced 
apoptosis in co-transfected and Aza-C-treated cells, indicating that it is a dominant negative mutant 
(Gober et al. 2003). Other studies revealed that H11 is silenced by aberrant DNA methylation in 60-
75% of melanoma and atypical nevi, but not in normal skin or most benign nevi. Methylation is 
inversely correlated with H11 expression. Aza-C induced H11/HSPB8 overload induces apoptosis 
in 55% of examined melanoma cultures. Apoptosis was determined by activation of caspases-9 and 
-3 and TUNEL, and was not seen in normal melanocytes. It was associated with H11/HSPB8 
complexation with TAK1 and activation of TAK1 and p38MAPK. TAK1 was not bound, nor 
activated by the H11/HSPB8 mutant W51C, which has dominant anti-apoptotic activity. β-catenin 
was phosphorylated at Ser
552
 by activated TAK1, inhibiting its nuclear accumulation and MITF and 
CyclinE/CDK2 expression. The activation of TAK1 also lead  to caspase-1 activation and beclin-1 
upregulation. The data indicate that H11/HSPB8 overload causes melanoma growth arrest and 
apoptosis through TAK1 activation and suggest that H11/HSPB8 is a promising molecular therapy 
target (Li et al. 2007,Smith et al. 2011, Smith et al. 2012). Other works showed that HSPB8 
overexpression markedly increase the effect of cyclin D1 which is paradoxically known to enhance 
radiation sensitivity (Trent et al. 2007). HSPB8 is known to interact in vitro and in vivo with Sam68 
(Src-associated protein in mitosis 68kDa), a multifunctional protein, known to govern cellular 
signal transduction, transcription, RNA metabolism, proliferation, apoptosis, and HIV-1 replication. 
The critical domain of HSP22 that interacts with Sam68 resides between amino acids 62 and 133. 
HSPB8 overexpression significantly inhibits Sam68 while HSP22 knockdown dramatically 
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increased both Sam68 mRNA and protein, altered cellular morphology, and enhanced cell 
proliferation. These results demonstrated for the first time that HSP22 regulates Sam68 expression 
and the ratio of Sam68 to HSP22 may determine the proliferative potential of glioblastoma cells 
(Modem et al. 2011, Badri et al. 2006). Promoter DNA methylation of HSPB8 was observed in 
hematopoietic tumor cell lines. HSPB8 expression could be restored after demethylation treatment 
with 5-aza-2′-deoxycytidine. Overexpression of HSPB8 reduced colony formation of both K562 
and Namalwa cell lines, inhibited the cell growth of Namalwa in vitro, and suppressed tumor 
formation of K562 cells in vivo demonstrating that overexpression of HSPB8 may have an 
antitumor activity in chronic myelogenous leukemia and lymphoma (Cui et al. 2012). 
 
HSPB8 in inherited peripheral neuropathies  
The distal hereditary motor neuropathies (dHMN) are a genetically heterogeneous group of diseases 
affecting the peripheral nervous system, characterized by distal lower-motor-neuron weakness. This 
is in contrast to Charcot–Marie–Tooth disease (CMT) and the hereditary sensory neuropathies 
where sensory involvement forms a significant component of the disease. Nevertheless, many forms 
of dHMN have minor sensory abnormalities, and there is an overlap between the axonal forms of 
CMT (CMT2) and dHMN. However, even when the phenotype is classified as CMT2, motor signs 
and symptoms predominate. Similarly, minor sensory involvement is also recognized in other motor 
syndromes including amyotrophic lateral sclerosis (ALS), Kennedy's disease and spinal muscular 
atrophy (SMA) (Irobi et al. 2004a, Fontaine et al. 2006, James et al. 2006, Rossor et al. 2012).  
Mutations in HSPB8 were first identified as a cause of dHMN by Irobi et al. which identified in four 
separate families two missense mutations targeting the same amino acid: a K141N, c.423G→C 
(Lys141Asn) in Belgian and Czech families; and a K141E, c.421A→G (Lys141Glu) in English and 
Bulgarian families (Irobi et al. 2004b). Subsequently, a K141N, c.423G→T (Lys141Asn) was 
reported in a large Chinese family with Charcot–Marie–Tooth disease type 2 (CMT2) (Tang et al. 
2005, Zhang et al. 2005). As said, the missense mutations K141N and K141E affect the same amino 
acid, a highly conserved lysine residue located in the central α-crystallin  domain of HSPB8. This 
Lys141 residue corresponds to the residue Arg120 that is mutated in αB-crystallin, causing a 
familial desmin-related myopathy (DRM) (Irobi et al. 2004b). Recently, Nakhro and colleagues 
identified a fourth  novel mutation K141T, c.422A→C (Lys141Thr) in the HSPB8 gene in a  
Korean axonal CMT patient who presented distal limb atrophy, sensory loss, areflexia, and axonal 
loss of large myelinated fibers (Nakhro et al. 2013). The mutation involves once again the same 
amino acid, suggesting Lys141 as a mutational hot spot for peripheral neuropathy development. 
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Despite the identification of these mutations, low mutation frequency is observed in the gene, with 
some works reporting low rate or no one mutations in the pedigrees studied (Rohkamm et al. 2007, 
Dierick et al. 2008, Capponi et al. 2011) and the pathological mechanisms of the diseases are not so 
well understood. Intriguingly, despite the ubiquitous presence of HSPB8, the motor signs and 
symptoms are much greater than the sensory manifestations and  only motor neurons appear to be 
affected by the K141N and K141E mutations which explain the predominant motor neuron 
phenotype in distal HMN and CMT2 (Irobi et al. 2010, Züchner et al. 2006).  It was proposed that 
mutations in the HSPB8 gene can result in a loss of function phenotype as suggested by the 
aggregation of the mutant protein into large formations leading to a reduction in the mitochondrial 
membrane potential in primary fibroblast of dHMN  patients and the inhibited  autophagy of  
misfolded protein in motor neuron-like NSC34 cells (Irobi et al. 2012, Kwok et al. 2011). 
Moreover, the last years have seen a growing list of evidence demonstrating that the mutations lead 
to dysfunctional intracellular trafficking and mitochondrial dynamics in CMT2 (Gentil et al. 2012). 
If these statements are correct, components that upregulate HSP‐expression will be useful for 
hereditary peripheral neuropathies. However, if mutant small HSPs act as toxic components that 
induce neuronal cell death, an upregulation of these mutant proteins could make the pathology even 
worse. Therefore, the ideal therapeutic strategy would be to selectively inhibit the expression of the 
mutant protein and maintain the expression of wild‐type proteins (Dierick  et al. 2005). 
HSPB8 in neurodegenerative diseases 
Many neurodegenerative disorders are characterized by conformational changes in proteins that 
result in misfolding, aggregation and intra- or extra-neuronal accumulation of amyloid fibrils. 
Molecular chaperones provide a first line of defense against misfolded, aggregation-prone proteins 
and are among the most potent suppressors of neurodegeneration known for animal models of 
human disease. Recent studies have investigated the role of molecular chaperones in amyotrophic 
lateral sclerosis, Alzheimer's disease, Parkinson's disease and polyglutamine diseases (Muchowski 
and Wacker 2005). Some members of the small heat shock proteins family, including HSPB8, have 
been shown to be up-regulated and involved in the protection of neurons from various stress 
condition (Bartelt-Kirbach and Golenhofen 2013). 
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Fig: 16. The small heat shock protein HSPB8: a pathway to clear misfolded proteins in nervous system disease.  
 
In 2005 Carra et al. investigated the capacity of  HSP22, to prevent protein aggregation in the 
CCL39 cells using the polyglutamine protein Htt43Q, a pathogenic form of huntingtin responsible 
for Huntington’s disease. In control conditions, Htt43Q accumulated in perinuclear inclusions 
composed of SDS-insoluble aggregates. Co-transfected with Htt43Q, HSPB8 became occasionally 
trapped within the inclusions; however, in most cells, it blocked inclusion formation. Biochemical 
analyses indicated that HSPB8 inhibited the accumulation of SDS-insoluble Htt43Q. This suggested 
that HSPB8 functions as a molecular chaperone, maintaining Htt43Q in a soluble state competent 
for rapid degradation. The C-terminal domain of HSPB8 contains the specific sequence necessary 
for chaperone activity. Neuropethies-associated mutations at Lys141 inhibited chaperone activity 
contributing to the development of the disease (Carra et al. 2005, Vos et al. 2010). The HSPB8 
activity is based on the formation of a stable complex between the protein and Bag3 (Bcl-2-
associated athanogene 3), a member of the co-chaperone family of Bag domain-containing proteins. 
Overexpressing Bag3 or HSPB8 stimulates the formation LC3-II, a key molecule involved in 
macroautophagy suggesting that the HSPB8-Bag3 complex might stimulate the degradation of 
Htt43Q by macroautophagy (Carra et al. 2008a). It was proposed that in the HSPB8-Bag3 complex, 
HSPB8 is responsible for recognizing the misfolded proteins whereas Bag3, through its proline-rich 
domain, might recruit and activate the macroautophagy machinery in close proximity to the 
chaperone-loaded substrates (Carra et al. 2008b). Biochemical methods indicate that the wild type 
HSPB8 forms tight complexes with Bag3 while K141E mutant weaker interact with Bag3 and that 
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the stoichiometry of complexes formed by HSPB8 and Bag3 is variable and is dependent on 
concentration of protein partners (Shemetov and Gusev 2011). The formation of the HSPB8–Bag3 
complex results from the interaction between the hydrophobic groove in the sHSP and two IPV (Ile-
Pro-Val) motifs in Bag3. The same IPV motifs are involved in the binding between Bag3 and wild-
type αB-crystallin and the αB-crystallin mutant R120G, and a mutation in one of these IPV motifs 
(P209L) has recently been associated with a severe dominant childhood muscular dystrophy with 
experienced development of cardiomyopathy and peripheral neuropathy, suggesting a possible 
important role for the sHSP–Bag3 complex formation in the development of human congenital 
diseases (Fuchs et al. 2009, Hishiya et al. 2011). The HSPB8-Bag3 complex is highly upregulated 
upon viral infection and aging and  induce the phosphorylation of the alpha-subunit of the 
translation initiator factor eIF2, which in turn causes a translational shut-down and stimulates 
autophagy (Carra 2009, Carra et al. 2009, Behl 2011). In a study aimed to analyze the involvement 
of NF-κB in basal and heat-stress-induced protein quality control, Nivon and colleagues showed 
that during heat shock recovery NF-κB activates selective removal of misfolded or aggregated 
proteins by controlling the expression of BAG3 and HSPB8 and by increasing  the level of the 
BAG3-HSPB8 complex (Nivon et al. 2012). A strong upregulation of HSPB8 and a moderate 
upregulation of BAG3 specifically in astrocytes in the cerebral areas affected by neuronal damage 
and degeneration were, finally, found in post-mortem human brain tissue from patients suffering of 
a series of protein conformation disorders such as Alzheimer's disease, Parkinson's disease, 
Huntington's disease and spinocerebellar ataxia type 3 (SCA3) (Seidel et al. 2012).  
 
Fig: 17. Participation of HSPB8-Bag3 complex  in regulated proteolysis of misfolded proteins (Mymrikov et al. 2011). 
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A study by Wilhelmus et al. observed HSPB8 expression in senile plaques (SPs),  pathological 
lesions characterizing Alzheimer’s disease (AD) and in cerebral amyloid angiopathy (CAA), the 
major pathological lesion in hereditary cerebral hemorrhage with amyloidosis of the Dutch type 
(HCHWA-D), caused by a mutation in the gene coding for the Aβ peptide. HSPB8 directly interact 
with wild-type Aβ1–42, wild-type Aβ1–40 or D-Aβ1–40 having the highest binding affinity with the 
Dutch mutation. Co-incubation of HspB8 with D-Aβ1–40 resulted in the complete inhibition of D-
Aβ1–40 -mediated death of cerebrovascular cells, likely mediated by a reduction in both the beta-
sheet formation of D-Aβ1–40 and its accumulation at the cell surface. HSPB8 also induced the 
production  of interleukin-6, interleukin-8, soluble ICAM-1 and monocyte chemoattractant protein 
1 in cultured astrocytes, suggesting a role as a mediator of the local inflammatory response 
associated with HCHWA-D and AD lesions (Wilhelmus et al. 2006, Wilhelmus et al. 2009, 
Bruinsma et al. 2011b).  
HSPB8 expression was found to be significantly increased in amyotrophic lateral sclerosis (ALS), 
where a mutation in the superoxide dismutase 1 (SOD1) gene leads to the production of a mutant 
SOD1. The mutant SOD1 misfolds, forms insoluble aggregates and impairs the proteasome. In 
spinal cord motor neurons, HSPB8 decreases aggregation and increases mutant SOD1 solubility and 
clearance via autophagy, without affecting wild-type SOD1 turnover (Anagnostou et al. 2010, 
Crippa et al. 2012a-b). 
HSPB8 was also related with Parkinson’s diseases. Bruinsma and colleagues showed that HSPB8 
was the most potent sHSP in inhibiting mature fibril formation of both wild-type and mutant α-
synuclein (A53T, A30P, E46K), suggesting that an optimization of the interaction between HSP22 
and α-synuclein may be an interesting target for therapeutic intervention in the pathogenesis of α-
synucleinopathies (Bruinsma et al. 2011a).  
Spinal and bulbar muscular atrophy (SBMA) is an X-linked motoneuron disease caused by an 
abnormal expansion of a tandem CAG repeat in exon 1 of the androgen receptor (AR) gene that 
results in an abnormally long polyglutamine tract (polyQ) in the AR protein. As a result, the mutant 
AR (ARpolyQ) misfolds, forming cytoplasmic and nuclear aggregates in the affected neurons. 
HSPB8 was shown to prevent AR65Q aggregation and facilitates the autophagic removal of 
misfolded aggregating species of ARpolyQ. Trehalose, an autophagy stimulator, induces HSPB8 
expression, suggesting that HSPB8 might act as one of the molecular mediators of the 
proautophagic activity of trehalose (Carra et al. 2005, Rusmini et al. 2013). 
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Fig: 18. The small heat shock protein HspB8 has been detected in neurodegenerative disorders such as Alzheimer's disease, 
Parkinson's disease, Huntington disease and spinocerebellar ataxia type 3, where it may function to protect cells from accumulation 
of insoluble protein aggregates. 
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MATHERIALS AND METHODS 
Bacterial strains 
Top 10: E.coli cells ideal for high-efficiency cloning and plasmid propagation. They allow stable 
replication of high-copy number plasmids and allow a transformation efficiency of 1 x 10
9
cfu/µg 
plasmid DNA. 
BL21(DE3) pLysS: E.coli cells belonging to a non-pathogenic strain capable of growing even in 
minimum medium. They allow the synthesis of large amounts of recombinant proteins due to the 
absence of some proteases. These cells are ideal for use with expression systems based on T7 
promoter. They are, in fact, engineered in such a way as to have steadily integrated into their 
genome the coding gene for T7 RNA polymerase that, when expressed, produces the enzyme T7 
RNA polymerase that can bind to T7 promoter and initiate transcription of downstream genes. The 
gene encoding the T7 RNA polymerase is placed under the control of the lac operon and this leads 
to an inhibition of gene transcription by the protein encoded by the gene repressor lacI, 
constitutively expressed in E.coli. However, due to the high activity of T7 RNA polymerase, cells 
can have basal levels of expression of the gene of interest. This can create problems if the gene of 
interest is toxic to bacteria. In this case, the expression of the toxic gene leads to selection of cells 
expressing the gene at minor level. These cells are often unable to express high levels of the gene of 
interest after induction with IPTG. The strain BL21pLysS solves this problem because it has a free 
plasmid pLysS able to express the enzyme lysozyme, which can inhibit transcription by the little 
RNA polymerase transcribed at basal level, forming with it a 1: 1 complex that is able to bind the 
promoter but can only produce abortive transcript (Zhang and Studier, 1997). The repression state 
of the gene can, however, be removed by adding to the culture medium IPTG (isopropyl-β-D-
thiogalactopyranoside), molecule similar to galactose that acts as inductor. The IPTG, take off the 
repressor lacI from the promoter allowing high levels of expression of T7 RNA polymerase, that is 
now able to overcome the inhibition of lysozyme. The RNA polymerase produced initiates the 
transcription from the T7 promoter. 
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Fig: 19. Mechanism of inhibition of bacteriophage T7 RNA polymerase by T7 lysozyme and induction mediated by IPTG. 
 
Praparation of competent E.coli  
Most method for bacterial transformation are based on the observations of Mandel and Higa (1970), 
who showed that bacteria treated with ice-cold solutions of CaCl2 and the briefly heated could be 
transfected with bacteriophage λ DNA (Mandel and Higa, 1970). The same method was 
subsequently used to transform bacteria with plasmid DNA and E.coli chromosomal DNA. 
Apparently, the treatment induces a transient state of competence in the recipient bacteria, during 
which they are able to take up DNAs derived from a variety of sources. Many variations of this 
basic technique have since then been described, all directed toward optimizing the efficiency of 
transformation of different bacterial strains by plasmid. Bacteria treated with the original protocol 
of  Mandel and Higa yield 10
5
-10
6 
transformed colonies/µg of supercoiled plasmid DNA, but this 
efficiency can be increased 100 to 1000 fold. To prepare competent E.coli cells we used a simple 
and rapid variation of the technique published by Cohen et al. in 1972, frequently used to prepare 
batches of competent bacteria that yield 5x10
6
 to 2x10
7
 transformed colonies/µg of supercoiled 
plasmid DNA. Competent cells made by this procedure may be preserved at -80°C, although there 
may be some deterioration in the efficiency of transformation during prolonged storage (Cohen et 
al. 1972). 
A single bacterial colony is picked up from a plate that has been incubated overnight at 37°C 
without antibiotic or with the antibiotic appropriate to the bacterial strain. The colony is transferred 
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in 50ml of LB and growth overnight at 37°C. The day after 2 ml of the culture are inoculated in 
200ml of LB and growth until the O.D. at 600nm reach 0.5. The culture is stored on ice for 30 
minutes and then divided into four  50ml falcon and centrifuged at 2200 rpm for 15 minutes at 4°C. 
The medium is discarded and the pellet resuspended in 50 ml of ice cold 0.1M CaCl2 and 
subsequently stored on ice for 50 minutes. The culture is centrifuged at 2200 rpm for 15 minutes at 
4°C and the pellet resuspended in 5ml of ice cold 0.1M CaCl2. 5ml of 30% glycerol in 0.1M CaCl2 
are added to the solution and the tube is inverted to ensure the mix of the two solutions. The 
competent cells are dispensed into aliquots and freeze in liquid nitrogen.  
PCR 
The polymerase chain reaction (PCR) is a technique developed in 1986 by Kary Mullis, allowing 
the multiplication (amplification) of fragments of nucleic acids of which you know the initial 
nucleotide sequences and terminals. The same method can be used to modify the sequence 
amplified or add new information and there is no need for this sequence to be present in pure form 
in the reaction mixture. PCR is used in all those situations where you have to amplify a DNA 
amount to levels useful for later analysis. PCR is robust, simple, speedy and flexible. 
The polymerase chain reaction contains several components: 
 A thermostable DNA polymerase to catalyze template-dependent synthesis of DNA 
 Deoxinucleoside triphosphates (dNTPs) 
 A pair of synthetic oligonucleotydes to prime DNA synthesis 
 Monovalent and divalent cations 
 Buffer to maintain pH 
 Template DNA 
A PCR cycle consists of 4 phases:  
 Denaturation step, where there is the separation of the DNA strands to be amplified. This 
phase is carried out at a temperature between 94 and 99 °C therefore using a DNA 
polymerase that isn't inactivated at high temperatures, such as Taq polymerase from the 
thermophilic bacterium Thermus aquaticus.  
 Annealing, where there is the annealing of primers with their complementary regions on the 
DNA sequence by lowering the temperature up to 40-55°C.  
 Extension phase, conducted at a temperature of 65-72° C, in which the Taq polymerase 
extends the segment of DNA from the primer using as template the single strand DNA. 
  Termination phase. 
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The cycle is repeated 30-40 times. In each cycle the DNA synthesized is duplicated, resulting in a 
chain reaction that allows extremely fast multiplication of the genetic material of interest. The 
length of the cycles and annealing temperature may vary depending on the length and composition 
of the DNA to be amplified and primer. 
At the end of the reaction the DNA is analyzed and recovered by agarose gel electrophoresis.  
 
Restriction enzymes and ligation 
The restriction endonuclease, or restriction enzymes, are a very important class of enzymes due to  
their ability to cut double helix DNA molecules at specific sites. Enzymes recognize, in fact, unique 
sequences of nucleotides in a very specific way. A DNA molecule that lacks a particular nucleotide 
sequence cannot be cut by a particular enzyme and this makes the DNA perfectly resistant to it, 
thereby making it easily recognizable. These enzymes have almost all bacterial origin and their 
physiological function is  to protect bacteria from viral attacks. In recombinant DNA technology, 
restriction enzymes are used in molecular cloning, which involves the introduction of a gene of 
interest in a DNA molecule called plasmid, able to replicate in a host system to produce large 
amounts of the gene or to allow its expression. So that the gene is inserted, both the plasmid DNA 
and the gene are treated with the same restriction enzyme: at the end of the reaction, both plasmid 
and gene will have similar terminals. In particular, if the enzyme used produces a staggered cut, 
cohesive ends produced will tend to associate in the presence of the enzyme DNA ligase, which 
catalyzes the reaction of ligation. For the digestion with restriction enzymes are usually used 5µl of 
DNA to digest, 2µl of reaction buffer specific for the enzyme used, 1µl of restriction enzyme and 
milliQ water until a reaction volume of 20 µl is reached. Digestion is carried out at 37°C for at least 
an hour. The ligation reaction is, instead, conducted at 15°C overnight and requires 3 µl of carrier 
DNA, 5 µl of insert DNA, 2 µl of enzyme, 1 µL of DNA ligase and de-ionized water until reaching 
a volume of 20 µl. 
 
Transformation of competent E.coli 
To transform the CaCl2-treated cells, 100µl of the suspension of competent cells are transferred into 
a 1.5ml eppendorf tube and mixed to no more than 50ng of plasmid DNA. The tube is stored on ice 
for 30 minutes and subsequently heat shocked for 30 seconds (in the case of BL21pLysS) or 90 
seconds (in the case of TOP10) before being rapidly transferred on ice in order to chill the cells for 
3 minutes. 1ml of SOC medium is added to the sample and the culture is incubated for 40 minutes 
at 37°C with vigorous shaking before being centrifuged at 4000 rpm for 5 minutes. The pellet is 
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resuspended with an appropriate volume of supernatant and transferred into a agar LB medium 
plate. The plate is incubated overnight at 37°C until the colonies appear.  
 
Agarose gel electrophoresis  
Electrophoresis through agarose gel is a simple technique, rapid to perform and capable of resolving 
fragments of DNA that cannot be separately adequately by other procedures. Furthermore, the 
location of DNA within the gel can be determinate directly by staining with low concentration of 
fluorescent intercalating dyes, such as ethidium bromide. Bands containing as little as 20pg of 
double-stranded DNA can be detected by direct examination of the gel in UV. DNAs from 50 bp to 
several megabases in length can be separated on agarose gel of various concentrations and 
configurations. Agarose is a linear polymer composed of alternating residues of D- and L- galactose 
joined by α-(1→3) and β-(1→4) glycosidic linkages. Chains of agarose forms helical fibers that 
aggregate into supercoiled structures with a radius of 20-30nm. Gelation of agarose results in a 
three dimensional mesh of channels whose diameters range from 50 nm to >200nm. The rate of 
migration of DNA through agarose gel is determinate by a lot of factors: 
 The applied voltage: at low voltage the rate of migration of linear DNA fragments is 
proportional to the voltage applied; 
 The presence of ethidium bromide in the gel: intercalation of ethidium bromide causes a 
decrease in the negative charge of the double stranded DNA that leads to a retardation of the 
rate of migration; 
 The molecular size of DNA: molecules of double-stranded DNA migrate through gel 
matrices at rates that are inversely proportional to the log10 of the number of base pairs; 
 The conformation of the DNA: supercoiled, circular and linear DNA migrates through 
agarose gel at different rates; 
 The type of agarose; 
 The electrophoresis buffer. 
The agarose gel electrophoresis is used to check the PCR products, the vectors and the genes 
necessary for the cloning and to analyze the plasmid DNA extracted from the bacteria. A 1% 
agarose gel is made by dissolving 0,8g of agarose into 80ml of TAE 1X buffer diluted from a 50X 
stock solution (2M Tris/HCl, 2M CH3COONa, 50 mM  EDTA). The solution is heated and mixed 
until the agarose is completely dissolved. When the solution has cooled until 40-50°C, the ethidium 
bromide is added to a final concentration of 0,5µg/ml. The gel is gently mix and poured into the 
mold. Once the gel is completely solid (about 30 minutes), it’s transferred into electrophoresis tank. 
The samples are mixed with the DNA gel-loading buffer (0,25% bromophenol blue, 30% glycerol 
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in H2O) and loaded into the slots of the gel. The run is conducted for about 30 minutes at 80 volts. 
If necessary, the bands of DNA can be recovered from the gel for other purposes. 
 
Recovery of DNA from agarose gel 
The recovery of DNA from agarose gel is performed with the use of the Illustra GFX PCR DNA 
and gel band purification kit (GE Healthcare), designed for the purification and concentration of 
DNA from PCR mixture, restriction enzyme digestions, solutions and agarose gel bands. DNA 
ranging in size from 50bp up to 100kbp can be purified from gel slices of up to 900mg. The kit uses 
a chaotropic agent to extract DNA from solution and/or to dissolve agarose and to denature 
proteins. DNA binds selectively to a silica membrane contained in the Illustra GFX microspin 
column. The matrix-bound DNA is washed with an ethanolic buffer to remove salts and other 
contaminants, and the purified DNA is eluted in a low ionic strength buffer. The yield of DNA is in 
the range of 60-80% and the purity of the sample is very high thanks to the removal of about 95% 
of the contaminants. 
Once the electrophoretic race is over, the agarose band containing the sample of interest is cut out 
and placed into a 1,5ml eppendorf to measure the weight of the slice. 10µl of capture buffer for 
each 10mg of gel slice are added, the tube is mixed by inversion and incubated at 55°C until the 
agarose is completely dissolved. The capture buffer-sample mix is transferred onto the assembled 
GFX Microspin column and collection tube. The assembled column and collection tube are spin at 
14000 rpm for 10 seconds and the flow is discarded by emptying the collection tube. 500µl of the 
wash buffer are added and the column is spin two times for 10 seconds and subsequently for 1 
minute at 14000 rpm. The GFX microspin column is transferred into a fresh 1,5ml microcentrifuge 
tube and 25µl of elution buffer are added. The DNA is eluted by centrifugation at 14000 rpm for 1 
minute.    
 
Miniprep  
After the transformation into TOP 10 cells, the DNA is extracted from cells using the miniprep 
(minipreparation) protocol which allows rapid small-scale isolation of plasmid DNA from bacteria. 
The method involves a phase of alkaline lysis of bacterial membrane followed by one neutralization 
step and one plasmid DNA purification step using subsequent high-speed centrifugations. The yield 
of DNA should be about 2-10 g. 
A single bacterial colony is inoculated into 2 ml of LB medium containing the appropriate antibiotic 
in a 15ml tube. The culture is incubated at 37°C for 5 hours with vigorous shaking. 
1,5ml of the culture are poured into a microfuge tube and centrifuged at 10000 rpm for 1 minute. 
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The medium is removed by aspiration and the pellet is resuspended in 100µl  resuspension buffer 
P1 (50mM Tris -HCl pH 7.5; 10mM EDTA  pH  8.0; 100µg/ml RNAse). 200µl lysis buffer P2 for 5 
minutes. 150µl of chilled neutralization buffer P3 (3.0 M potassium acetate pH 5.5) are added to the 
sample and the latter is immediately mixed by vigorously inverting 4-6 times and incubated on ice 
for 5 minutes and then centrifuged at 12000 rpm for 5 minutes in a microfuge. 
After centrifuging the supernatant is transferred to a fresh tube and the double-stranded DNA is 
precipitated  with 2 volumes (800µl) of absolute ethanol at room temperature. After 5 minutes on 
ice the sample is centrifuged at 12000 rpm for 5 minutes and the supernatant is removed  while the 
pellet is rinsed with 400µl of 70% ethanol at 4°C. The supernatant is discarded and the pellet air 
dried for 10 minutes and subsequently redissolved in 20µl of milliQ water.  
The purified plasmid DNA is analyzed by cleavage with the appropriate restriction enzymes. 
 
Maxiprep 
This technique allows us to isolate DNA from the positive colonies in a more pure form and in 
major yields. To do this we use the Plasmid Purification Kit (QIAGEN), based on a modified 
alkaline lysis procedure, followed by binding of DNA to an anion exchange resin under appropriate 
low salt and pH conditions. RNA, proteins, dyes and low molecular weight impurities are removed 
by a medium salt wash. Plasmid DNA is eluted in a high salt buffer and the concentrated and 
desalted by isopropanol precipitation. The protocol is designed for preparation of up to 100µg of 
plasmid. 
A culture of 100ml LB medium containing the appropriate selective antibiotic is inoculated with a 
single colony from a freshly streaked selective plate and growth overnight at 37°C with vigorous 
shaking (300 rpm). The bacterial cells are harvested by centrifugation at 3800 rpm for 20 minutes at 
4°C and the bacterial pellet is resuspended in 5 ml of resuspension buffer P1 (50mM Tris -HCl pH 
7.5; 10mM EDTA  pH  8.0; 100µg/ml RNAse). 5ml of lysis buffer P2 (200mM  NaOH;  1%  SDS) 
are added and the tube is inverted 4-6 times and incubated at room temperature for 5 minutes. 5ml 
of chilled neutralization buffer P3 (3.0 M potassium acetate pH 5.5) are added to the sample and the 
latter is immediately mixed by vigorously inverting 4-6 times and incubated on ice for 15 minutes. 
The precipitation is enhanced by using chilled buffer P3 and incubating on ice. After addiction of 
buffer P3, a fluffy white materials forms and the lysate becomes less viscous. The precipitated 
material contains genomic DNA, proteins and cell debris. The sample is centrifuged at 11000 rpm 
for 30 minutes at 4°C and the supernatant containing plasmid DNA is applied to a Qiagen-tip 
previously equilibrated with 4ml of equilibration buffer QBT (750mM NaCl; 50mM MOPS pH 7.0; 
15% isopropanol; 0.15% Triton X-100). The column is washed two times with 10ml of wash buffer 
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QC (1.0M NaCl; 50mM MOPS pH 7.0; 15% isopropanol) and the DNA eluted with 5ml of eluition 
buffer QF (1.25M NaCl; 50mM Tris-HCl pH 8.5; 15% isopropanol). The DNA is precipitated by 
adding 3.5ml of room temperature isopropanol and by centrifuging at 12000 rpm for 30 minutes at 
4°C. The pellet is washed with 2ml of room temperature 70% ethanol and air-dried for 10 minutes 
before being redissolved in a suitable volume of MilliQ water or buffer.     
 
Large-scale production of proteins 
For a larger scale production of proteins, bacterial plate is washed with a few milliliters of LB 1X 
and the bacteria so resuspended are placed  in a 2-liters conical flask with two liters of LB 1X.  1ml 
of 100 µg/ml antibiotic ampicillin is added to the culture. The 2 liters of culture are divided into 4 
flasks (500 ml each) in order to increase the aeration and put at 37°C with vigorous shaking . The 
bacteria are grown until the optical density at 600 nm reach 0.6 and at this point they are induced 
with IPTG to a final concentration of 100 µg/ml. After induction culture is left in agitation for 3 
hours before being centrifuged for 20 min at 6000 rpm at 4°C. The supernatant is removed while 
the pellet is resuspended in a few milliliters of PBS. 
 
Proteins purification 
The purification of protein engineered to contain a histidine tag is perfomed through IMAC 
(immobilized metal ion affinity chromatography). This technique has a very high efficiency, 
capacity, concentrating power and speed. Polyhistidine tracts bind tightly to a resin charged with 
divalent nickel ions. Contaminating protein can be removed with appropriate washing, and the 
protein of interest can then be eluted by a soluble competing chelator. Because few natural proteins 
bind with significant affinities to such matrices, His-tagged proteins can be purified substantially in 
a single step. Purification can be performed both under native and denaturing conditions. When the 
proteins are purified in denaturing conditions, bacteria are lysed by sonication in 6 M guanidinium 
chloride pH 8.0 and then centrifuged at 13000 rpm for 30 min at 4°C. Meanwhile the resin (approx. 
3 ml of His-select Nickel resin) is washed with approximately 15 ml of H2O milliQ to remove 
ethanol and with 15 ml of sonication buffer. After centrifugation, the supernatant bacteria is put in 
agitation with the resin in a bottle for about an hour to allow the binding of the protein to the resin. 
The resin is then put back in the column and washed with 70 ml of 6 M guanidinium chloride at pH 
8.0 and 70 ml of urea at pH 8.0. The protein is eluted from the column with urea pH 4.5 and 
collected in fractions of 1 milliliter. The final concentration is calculated by measuring the 
absorbance at a wavelength of 280 nm. When the proteins are purified in native conditions, the 
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same steps are followed but the sonication is performed in the appropriate buffer and the protein is 
eluted with imidazole. 
 
Fig: 20. Scheme of protein purification using the Ni-NTA system. 
SDS-Page 
The SDS-polyacrylamide gel electrophoresis is carried out in polyacrylamide gels under condition 
that ensure dissociation of the proteins into their individual polypeptide subunits and that minimize 
aggregation. This technique is based on the use of the strongly anionic detergent SDS (sodium 
dodecyl sulfate) in combination with a reducing agent (such as β mercaptoethanol or DTT) and heat 
to dissociate the protein before they are loaded into the gel. The denatured proteins bind SDS and 
become negatively charged. Because the amount of SDS bound is almost proportional to the 
molecular weight of the polypeptide and is independent of its sequence, SDS-protein complexes 
migrate through the gel in accordance with the size of the polypeptide. By using markers of known 
molecular weight, it is possible to estimate the molecular weight of the polypeptide. The 
polyacrylamide gel is composed of two parts: a stacking gel and a resolving gel. Once the proteins 
have passed the stacking gel of high porosity, they are  deposited in a very thin zone on the surface 
of the resolving gel and they can start the real separation through the gel. Polyacrylamide gels are 
composed of chains of polymerized acrylamide that are cross-linked by a bifunctional agent such as 
N, N’-methylene-bis-acrylamide. The effective range of separation depends on the concentration of 
polyacrylamide used to cast the gel and on the amount of cross-linking. The sieving properties of 
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the gel are determined by the size of the pores, which is a function of the absolute concentration of 
acrylamide and bisacrylamide used to cast the gel. 
Once the glass plates are assembled, the resolving gel (30% acrylamide-bisacrylamide solution, 
1,5M Tris HCl  pH 8,8, 10% SDS, 10% ammonium persulfate, H2O milliQ, TEMED) is poured into 
the gap between the glass plates. Few microlitres of isopropanol are used to overlay the 
polyacrylamide solution. After polymerization is complete (30 minutes), the overlay is poured off 
and the top of the gel is washed several times with deionized  H2O  to ensure the removal of any 
unpolymerized acrylamide. The stacking gel (30% acrylamide-bisacrylamide solution, 1M Tris HCl  
pH 6,8, 10% SDS, 10% ammonium persulfate, H2O milliQ, TEMED)  is poured directly onto the 
surface of the polymerized resolving gel and a comb is inserted to form the slots in the gel. Before 
the run the sample is resuspended in an appropriate volume of 1X SDS gel loading buffer (50mM 
Tris HCl pH 6,8, 100mM DTT, 2% SDS, 0,2% bromophenol blue, 10 % glycerol). The run is 
performed in a 1X Tris-glycine electrophoresis buffer (25mM Tris base, 250mM glycine, 0,1% 
SDS) at 25 mA and maximum voltage until the bromophenol blue reaches the bottom of the 
resolving gel. Once the run is over, the gel is stained with Coomassie Brilliant Blue R-250 and 
destained by soaking in methanol: acetic acid solution. 
Western blotting 
Western blotting was introduced by Towbin et al. in 1979 and is now a routine technique for protein 
analysis (Towbin et al. 1992). Western blotting, also called protein blotting or immunoblotting, uses 
antibodies to identify specific protein targets bound to a membrane; the specificity of the antibody-
antigen interaction enables a target protein to be identified in the midst of a complex protein 
mixture. Western blotting can produce qualitative and semi-quantitative data on a protein of 
interest. After electrophoresis, the separated proteins are transferred, or "blotted", onto a solid 
support matrix, which is generally a nitrocellulose or polyvinylidene difluoride (PVDF) membrane. 
PVDF membranes are highly hydrophobic and must be pre-wetted with methanol or ethanol prior to 
submersion in transfer buffer. The gel to be blotted is briefly wetted with the transfer buffer (39 mM 
glycine, 48 mM Tris base, 0.037% SDS, 20% methanol) and then put on the PVDF membrane sheet 
and care is taken to remove all air bubbles. The gel and the PVDF membrane are placed between 
two sheets of Whatman 3MM paper and the assembly is put into an electrophoretic chamber with 
the PVDF sheet facing the cathode.  
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Fig: 21. Schematic representation of an electrophoretic chamber. 
 
The transfer of the protein is performed at 350 mA for 1 hour.  
The membrane supports used in Western blotting have a high affinity for proteins. Therefore, after 
the transfer of the proteins from the gel, it is important to block the remaining surface of the 
membrane to prevent nonspecific binding of the detection antibodies during subsequent steps. In 
order to achieve the saturation of the PVDF membrane, the latter is placed in TBS (50 mM Tris 
HCl, 150 mM NaCl, pH 8.0) + 3% BSA (Bovine serum albumin) for 1 hour or overnight at room 
temperature with gentle agitation on a platform shaker. The membrane is, then, incubated with the 
primary antibody (diluted at the right concentration), that is able to recognize the target protein, for 
1 hour or overnight and then washed twice with TBS  + 1% BSA + 0,1% Tween 20 for 15 minutes 
in order to remove nonspecifically bound material and unbound primary antibody. At this point the 
membrane is exposed to a secondary antibody, directed at a species-specific portion of the primary 
antibody, that is linked to biotin or to a reporter enzyme such as alkaline phosphatase or horseradish 
peroxidase. After the unbound probes is washed away, by incubating twice with TBS  + 1% BSA + 
0,1% Tween 20 for 15 minutes,  the western blot is ready for detection of the probes that are labeled 
and bound to the protein of interest. The detection is made through ECL (enhanced 
chemiluminescence) in the case of the horseradish peroxidase and through NBT (Nitro blue 
tetrazolium chloride) / BCIP (5-Bromo-4-chloro-3indolyl phosphate) when the alkaline phosphatase 
is used. 
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Circular dichroism 
Circular dichroism (CD) is the difference in the absorption of left-handed circularly polarised light 
(L-CPL) and right-handed circularly polarised light (R-CPL) and occurs when a molecule contains 
one or more chiral chromophores (light-absorbing groups).  
  
Circular dichroism = ΔA(λ) = A(λ)LCPL - A(λ)RCPL, where λ is the wavelength 
  
Circular dichroism (CD) spectroscopy is a spectroscopic technique where the CD of molecules is 
measured over a range of wavelengths. CD spectroscopy is used extensively to study chiral 
molecules of all types and sizes, but it is in the study of large biological molecules where it finds its 
most important applications. The vast majority of biological molecules, in fact, are chiral. For 
instance, 19 of the 20 common amino acids that form proteins are themselves chiral, as are a host of 
other biologically important molecules, together with the higher structures of proteins, DNA and 
RNA. The highly chiral chemistry of biological molecules lends itself well to analysis by circular 
dichroism. A primary use is in analysing the secondary structure or conformation of 
macromolecules, particularly proteins. As secondary structure is sensitive to its environment, 
temperature or pH, circular dichroism can be used to observe how secondary structure changes with 
environmental conditions or on interaction with other molecules. Structural, kinetic and 
thermodynamic information about macromolecules can be derived from circular dichroism 
spectroscopy. 
Measurements carried out in the visible and ultra-violet region of the electro-magnetic spectrum 
monitor electronic transitions, and, if the molecule under study contains chiral chromophores then 
one CPL state will be absorbed to a greater extent than the other and the CD signal over the 
corresponding wavelengths will be non-zero. A circular dichroism signal can be positive or 
negative, depending on whether L-CPL is absorbed to a greater extent than R-CPL (CD signal 
positive) or to a lesser extent (CD signal negative). Circular dichroism spectra are measured using a 
circular dichroism spectrometer. CD spectrometers measure alternately the absorption of L- and R-
CPL, usually at a frequency of 50kHz, and then calculate the circular dichroism signal. 
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Fig: 22. Standard circular dichroism spectra of α-helix, β-sheet and random coil structures. 
 
Interaction  analysis  on  Biacore  via  surface  plasmon  resonance  (SPR)   
SPR experiments are performed using a Biacore 3000 system (GE Healthcare, Uppsala, Sweden) 
setting both sensor and sample temperature at 25°C and using 10 mmol/L Hepes (pH 7.4), 150 
mmol/L NaCl, 3 mmol/L EDTA, and 0.05% v/v surfactant P20 as running buffer. Three flow cell 
surfaces are activated by 1:1 mixture of N-hydroxysuccinimide and N-ethyl-N-
(dimethylaminopropyl) carbodiimide for 7 min (flow rate 5 µL/min). Afterwards, all proteins are 
immobilized on parallel channels of the sensor chip CM5, using amine coupling chemistry 
according to the manufacturer’s protocol. Residual  binding  sites  on  the  sensor  chip  surface  are 
blocked  with  a  7  min  injection  of  1  mol/L  ethanolamine,  pH  8.0.  A  reference  cell  is  
always prepare in parallel by the same immobilization procedure (activation/deactivation step) 
without protein addiction. After the binding experiment the sensor chip is regenerated by a 1 minute 
injection with 10nm/L glycine pH 2,5. Response time at start of injection is always reported as the  
difference between signals arising from the active and the reference cell which, if necessary, was 
additionally corrected for baseline drift and bulk refractive index contribution. The observed curves  
are fitted assuming single phase kinetics (single phase dissociation/association). The kinetic and  
thermodynamic parameters were calculated from the fits using BIA evaluation software (version 4.1 
BIACORE, GE Healthcare). 
 
Cell cultures and transfection 
Experiments are carried out with Chinese hamster ovary (CHO), HeLa or SKNBE cells, cultured in 
75-cm
2
 flasks (37°C, 5% CO2 atmosphere), using Ham's F12 medium (for CHO) or DMEM 
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medium (for HeLa and SKNBE) supplemented with 10% fetal calf serum, penicillin (100 U/mL), 
and streptomycin (100 µg/mL). The cells, seeded onto glass coverslips at 4.5x10
4
 cells/cm
2
 were 
transiently transfected with the Lipofectamine Plus reagent (Invitrogen). DNA is diluted and mix 
with Plus reagent. The mix is incubated at room temperature for 15 minutes. Lipofectamine reagent 
is diluted in a second tube with OPTIMEM medium without serum and then mixed with the pre-
complexed DNA. The mix is incubated at room temperature for 15 minutes and then added to each 
well of cells containing fresh OPTIMEM medium. To optimize proteins expression, 6 hours after 
transfection the medium was changed, and cells were kept at 30°C for 48h for immunolabeling   
assays. For image analysis cells are cultured on coverslips and transfected as above, washed with 
PBS (phosphate saline buffer), permeabilized with Triton X-100 and fixed with 2% 
paraformaldeyde followed by incubation with the antibody of interest. Coverslips are mounted onto 
glass microscope slides and analyzed with fluorescence microscopy. For western blot analysis, cells 
are transiently transfected. Two days after transfection, 2–3 × 106 cells are collected with PBS and 
one quarter of the sample is resolved by SDS-Page, blotted onto a PVDF membrane and probed 
with the appropriate antibody. 
 
Co-immunoprecipitation 
Co-immunoprecipitation (Co-IP) is a popular technique to identify physiologically relevant protein-
protein interactions by using target protein-specific antibodies to indirectly capture proteins that are 
bound to a specific target protein. These protein complexes can then be analyzed to identify new 
binding partners, binding affinities, the kinetics of binding and the function of the target protein. 
3×10
6
 cells are transiently transfected with the appropriate plasmid. Two days after transfection the 
cells are treated with the protein of interest and after 4  h lysed in 250 µL of 50 mmol/L Tris-HCl, 
pH 7,5, 150 mmol/L NaCl, and 1% v/v Triton X-100, plus protease inhibitors for 15 min on ice, 
followed by two sonication pulses. Protein extracts (800 µg) are incubated with 20 µL of NinTA 
beads (Sigma) for 8 h at 4°C. Beads are washed three times with wash buffer (50 mmol/L Tris-HCl,  
150 mmol/L NaCl, pH 7,4), and proteins are eluted by incubating the beads with 8 mol/L urea, 50 
mmol/L Tris-HCl pH 8 for 10 min at room temperature. The eluted is resolved by SDS-PAGE, 
blotted onto a PVDF membrane and probed with the antibodies of interest. 
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RESULTS 
 
Prion protein-Tyrosine hydroxylase interaction 
Construction of plasmids for PrP 
The expression plasmids encoding recombinant E.coli-derived human (hu: 23-230), mouse (mu: 23-
231), hamster (ha: 29-231), bovine (bo: 25-242) and ovine PrP (sh: 25-234) and human doppel 
(Dpl: 28-152) were already present in our laboratory (described in Negro et al. 1997; Negro et al. 
2000 and Cereghetti et al. 2004). The human PrP deletion mutants 23-90 and 94-230 were 
constructed in the same way using the following primers: 
5’ggcggatccaagaagcgcccgaagcctggagga 3’, 5’ ggcggatccggcacccacagtcagtggaacaag 3’ 
5’gcggaattcaaccccagccaccaccatgaggct 3’, 5’ gcggaattcacgatcctctctggtaataggcctg 3’ 
A TAT-PrP fusion protein was produced by introducing the DNA sequence coding for the 23-230 
amino acid sequence for huPrP in plasmid pTAT-Neuroglobin (described in Peroni et al. 2007) 
between NheI and EcoRI restriction sites using the following primers: 
5’gtagctagcaagaagcgcccgaagcctggagga 3’, 5’ agtgaattcacgatcctctctggtaataggcctg 3’ 
 
Construction of plasmids for TH 
The TH human gene was amplified by PCR from a template (kindly provided by Prof. J. Haavick,  
University of Bergen, Bergen, Norway) containing the full-length coding sequence of human TH 
isoform 1 using the following primer: 
5’ cacgctagatgcccacccccgacgccacca 3’, 5’ cggaattctagccaatggcactcagcgcatg 3’ 
The PCR product was cut with NheI and EcoRI, and cloned into pRSETA (Invitrogen), pTAT-
Neuroglobin and pEGPF (Clontech) plasmids to give, respectively  pRSET-TH, pTAT-TH and 
pcDNA-TH. pEYFP-TH was produced by cloning TH in pEYFP between NheI and EcoRI. The TH 
sequences 1-497 and 150-497 were also sub-cloned into pPROEX vector (Invitrogen) using the 
following primers: 
5’ aattcggcgccatgcccacccccgac 3’, 5’ ggacgccgggtacctagccaatggca 3’ for 1-497; 
5’ aattcggcgccatgtcagaggacgtgc 3’, 5’ ggacgccgggtacctagccaatggca 3’ for 150-497. 
 
The PCR product was cut with NarI and KpnI and cloned in the same sites of plasmid pPROEX to 
give plasmids pRPROEX TH(1-497) and pRPROEX TH(150-497). TH(1-152) cDNA was sub-
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cloned into pET28 and pET3a vectors (Novagen), with NdeI and BamHI sites for expression with or 
without the His-tag, respectively, using the following primers: 
5’ ggagatatacatatgcccaccccc 3’, 5’cggggatccgcacgtcctatgac 3’ 
 
The TH amino acid coding sequences 1-497, 1-184 and 150-497 were also sub-cloned in pcDNA-
mRuby2 (Addgene) using the following primers: 
5’cccaagcttatgcccacccccgacgccaccacg 3’, 5’cgtggatccgagccaatggcactcagcgcatgg 3’ for 1-497; 
5’cccaagcttatgcccacccccgacgccaccacg 3’, 5’ gctggatcctctgacacctggcgcacacaccactg 3’ for 1-184; 
5’ cccaagcttatgaggccgcgagctgggggcccca 3’, 5’cgtggatccgagccaatggcactcagcgcatgg 3’for 150-497. 
 
Each amplified product was cut with HindIII and BamHI and cloned in the same restriction site of 
plasmid pCDNA-mRuby2 (Addgene) in order to give plasmids pTH(1-497)-Ruby2, pTH(1-184)-
Ruby2 and pTH(150-497)-Ruby2, respectively. 
 
The nucleotide sequences of the plasmids were analyzed for correctness by BMR genomics 
(Padova, Italy). 
 
Recombinant protein expression and purification 
Plasmids pRPROEX TH(1-497), pRPROEX TH(150-497), pRSET-TH, pET28 TH(1-152), pET3a 
TH(1-152) and pTAT-TH were introduced in BL21(DE3) E.coli. TH(1-497) was produced 
overnight at 16°C, while TH(150-497), pRSET-TH and pTAT-TH expression was carried out at 
28°C for 5 h. All proteins were expressed with an N-terminal His-tag and purified following 
established procedures by HisTrap immobilized metal affinity chromatography (IMAC) FF (GE 
Healthcare) and Superdex 200 HR 10/30 gel-filtration chromatography (Amersham Bioscience). 
The His-tag was removed by incubation with TEV protease and by an additional IMAC step. For 
activity assay, TH(1-497) and TH(150-497) were dialyzed against 50 mmol/L HEPES (pH 7.0), 100 
mmol/L KCl and 2 mmol/L dithiothreitol (DTT), concentrated to 1-2 mg/mL by ultrafiltration 
(Vivaspin) and frozen in liquid nitrogen in the presence of 30% v/v glycerol. For binding 
experiments, TH buffer was exchanged for 20 mmol/L sodium phosphate (pH 7.4), 100 mmol/L 
NaCl. TH(1-152) protein from plasmids pET28 and pET3a was purified from inclusion bodies by a 
series of 30-min stirred washes at room temperature (RT), with centrifugation at 10,000g for 30 min 
at 4°C. The first wash was with 20 mmol/L Tris-HCl (pH 7.4) containing 150 mmol/L NaCl, 2 
mmol/L MgCl2, 0.5 mmol/L CaCl2 and 50 U of DNase /RNase per liter of culture, followed by 20 
mmol/L Tris-HCl (pH 8.0), 200 mmol/L NaCl, 1% v/v sodium deoxycholate and 2 mmol/L EDTA. 
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The resulting pellet was taken up in 20 mmol/L Tris-HCl (pH 8.0), 1 mmol/L EDTA and 0.25% v/v 
sodium deoxycholate, and this step performed twice. The insoluble fraction was then solubilized in 
20 mmol/L sodium phosphate (pH 7.4), with 500 mM NaCl and 5 M urea, the suspension stirred for 
another 30 min, then centrifuged for 20 min at 28,000g. The urea was gradually removed by step 
dialysis over 48 h at 4°C against 20 mmol/L sodium phosphate (pH 7.4) buffer containing 100 
mmol/L NaCl. The successfully refolded protein was separated by centrifugation (28,000g, 30 min 
at 4°C) and concentrated with an Amicon device (Millipore). TAT-TH was solubilized from the 
bacterial pellet in 8 mol/L urea, 100 mmol/L NaCl, 10 mmol/L imidazole and 20 mmol/L Tris–HCl 
(pH 8.0), and applied onto the pre-equilibrated Ni–NTA column at RT (Wu et al. 2006). After 
extensive washing the fusion protein was eluted from the Ni–NTA column with 500 mmol/L 
imidazole, pH 6.3. The purified fractions were pooled and dialyzed in 0.1 mmol/L reduced 
glutathione, 0.01 mmol/L GSSG, 100 mmol/L NaCl, and 20 mmol/L Tris–HCl, pH 8.0 to remove 
the urea, and then dialyzed against phosphate-buffered saline (PBS). All purified proteins were 
aliquoted and stored at 80°C until used. 
 
SDS- PAGE, Western blotting and dot-blot assay 
Mini SDS-PAGE was performed using the electrophoresis MiniVE (Amersham) system according 
to the manufacturer’s instructions. Protein samples were diluted in Laemmli sample buffer (50 
mmol/L Tris-HCl pH 6.8, 100 mmol/L DTT, 2% (w/v) SDS, 0.05% (w/v) bromphenol blue) and 
heated for 5 min at 100°C. Each well of a 12% SDS-PAGE was loaded with 1 μg total proteins. 
Separated proteins were electrotransferred onto Immobilon-P polyvinylidene difluoride (PVDF) 
membranes (Millipore) with the mini VE System Blot Module (Amersham). For TH and its deletion 
mutants the proteins were directly blotted onto the Bio-Dot Apparatus Microfiltration (Biorad) 
following the manufacturer’s instructions. Non-specific binding sites on the membrane were 
blocked with PBS containing 5% (w/v) bovine serum albumin (BSA) (Sigma-Aldrich) and 50  
mol/L Tris/HCl, 150 mmol/L NaCl. For Far Western blots the membrane was incubated with 10 mL 
of TH (10 μg/mL) or its deletion mutants in blocking buffer. Dot blot membranes were incubated 
with 10 mL of 10 μg/mL recombinant HuPrP. Membranes were washed 3 x 5 min with PBS/1% 
BSA, 0.1% Tween 20. TH bound to PrP or vice versa was detected by incubation with 0.4 mg/mL 
of anti-TH monoclonal antibody (MMS-503P) (Covance, CA) or 0.5 mg/mL of anti-PrP mAb 3F4 
(DAKO, Glostrup, Denmark) in blocking buffer for 1 h at room temperature followed by incubation 
with 50 ng/mL horseradish peroxidase-conjugated goat anti-mouse IgG mAb (Sigma-Aldrich) for 
45 min at room temperature. The blot was developed using the NBT/BCIP (Roche). 
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Fig: 23. Far Western blot and dot blot analyses of prion proteins with tyrosine hydroxylase. 
Panel (A) Recombinant human Dpl, the deletion forms huPrP(23-90) and huPrP(94-230), the full length huPrP(23-230), muPrP(23-
231), haPrP(29-231), bovine PrP(25-242), and sheep PrP(25-234) were separated by 13% SDS-PAGE. The same proteins in panel B 
after transfer on nitrocellulose were probed with 25 μg/mL recombinant human TH(1-497) and developed with an anti-TH antibody. 
See text for details. Note that TH is unable to recognize the N-terminal un-structured domain of huPrP(23-90), as well as human Dpl 
protein. Panel (C) Dot blot analyses of TH interaction with human PrP. Serial dilutions (μg) of full length TH(1-497)and its deleted 
mutants TH(1-152) and TH(150-497),were blotted onto nitrocellulose before probing with 20 μg/mL huPrP(23-230) followed by 
development with antibodies against huPrP (3F4). 
 
The results obtained from western blot and dot blot analyses reveal that PrP of mouse, hamster,  
bovine and ovine origin showed similar behaviors, all being involved in the interaction with TH. 
Human Dpl, which adopts the same secondary/tertiary structure as PrP, was not recognized by TH, 
indicating that sequence recognition is essential for an effective binding of PrP to TH. Moreover, 
huPrP(23-90) was not recognized by TH, suggesting that TH recognized the structured C-terminal 
sequence of PrP but failed to recognize its N-terminal un-structured domain. The TH deletion 
mutant 1-152 also recognized PrP albeit less robustly than full-length TH, while the C-terminal 
catalytic and tetramerization domains of TH(150-497) did not recognize PrP at all (data not shown). 
Binding specificity was further validated by the fact that TH did not indiscriminately recognize 
proteins of similar molecular weight that were transferred onto the PVDF membrane. Far Western 
blotting was effective only with PrP bound to the PVDF membrane and using TH as analyte; no 
TH-PrP interaction was observed when TH was bound to the PVDF membrane and PrP used as 
analyte. Indeed, PrP was able to refold after SDS-driven denaturation at 100°C (provided that SDS 
is removed), while subjecting TH to such treatment resulted in loss of structure, as TH denaturation 
is an irreversible process (Gahn et al. 1995). The dot blot assay, which does not require a protein 
 63 
 
denaturation step, was therefore used. The results show that huPrP(23-230) recognizes full-length 
TH and its deletion mutant (1-152) but not the catalytic domain (150-497) mutant. Collectively 
these data provide evidence for the N-terminal regulatory domain TH(1-150) interacting with the 
PrP C-terminal domain. 
 
Interaction analysis on Biacore via surface plasmon resonance (SPR) 
SPR experiments were performed using a Biacore 3000 system (GE Healthcare, Uppsala, Sweden) 
setting both sensor and sample temperature at 25°C and using 10 mmol/L Hepes (pH 7.4), 150 
mmol/L NaCl, 3 mmol/L EDTA, and 0.05% v/v surfactant P20 as running buffer. Three flow cell 
surfaces were activated by 1:1 mixture of N-hydroxysuccinimide and N-ethyl-N-
(dimethylaminopropyl) carbodiimide for 7 min (flow rate 5 μL/min). Afterwards, all proteins were 
immobilized on parallel channels of the sensor chip CM5, using amine coupling chemistry 
according to the manufacturer’s protocol. Specifically, the PrP forms huPrP(94-230), haPrP(29-
231) and haPrP(90-231), diluted in 10 mmol/L sodium acetate buffer (pH 5.0) and TH diluted in 10 
mmol/L sodium acetate buffer (pH 4.0), were injected for 8-10 min at a flow rate of 5 μL/min. 
Residual binding sites on the sensor chip surface were blocked with a 7 min injection of 1 mol/L 
ethanolamine, pH 8.0. A reference cell was always prepared in parallel by the same immobilization 
procedure (activation/deactivation steps) without protein addition. 
All binding experiments between TH and PrP proteins were carried out at a constant flow rate of 30 
μL/min running buffer, unless otherwise specified. To determine the affinity of TH toward PrP, 60 
μL aliquots of TH(1-497) and TH(150-497), as analyte, at various concentrations (within the range 
0.1 μmol/L to 1.0 μmol/L, were injected over the three PrP-immobilized sensor chips (association 
phase), followed by a 10-min washing step with the running buffer (dissociation phase). The sensor 
surface was then regenerated by a 1-min injection with 10 mmol/L glycine, pH 2.5, to remove TH. 
The N-terminus TH(1-152) was not examined by SPR, owing to its intrinsic instability and 
insolubility that hampered protein immobilization on sensor chips. Response time at start of 
injection was always reported as the difference between signals arising from the active and the 
reference cell which – if necessary – was additionally corrected for baseline drift and bulk refractive 
index contribution. The observed curves were fitted assuming single phase kinetics (single phase 
dissociation/association). The kinetic and thermodynamic parameters were calculated from the fits 
using BIA evaluation software (version 4.1 BIACORE, GE Healthcare, Uppsala, Sweden). 
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The catalytic domain of TH(150-497) did not interact with any of the PrP forms, whereas a strong 
interaction between TH(1-497) and both human and hamster PrPs was recorded. The kinetic and 
thermodynamic association and dissociation constants obtained are shown in table 
 
 
Fig: 24. Kinetic parameters and dissociation constants for interaction between TH(1-497) and PrP.  
 
Thermodynamic evaluation of the interaction between TH(1-497) and PrP yielded equilibrium 
dissociation constants (KD) of 2.2 nM, 2.8 nM and 5.0 nM for hamster full-length haPrP(23-231), 
truncated haPrP(90-231) and huPrP(90-230), respectively. The experiments were repeated by 
injecting the selected PrP (as analyte) at concentrations of 0.5-10.0 μM (in running buffer) over 
TH(1-497) immobilized on the sensor chip. Sensorgrams for the interaction of TH(1-497) with 
haPrP(90-231) and haPrP(29-231) are shown in fig. 25A and 25C, respectively, while fig. 25B and 
25D show the dose-response SPR signal versus the concentration of haPrP(90-231) and haPrP(29-
231), respectively. These latter curves are indicative of a specific interaction. Applying global 
fitting to evaluate the interaction parameters of PrP with TH(1-497) immobilized on the sensor chip 
revealed high-affinity binding, with KD values of 95.0 nM, 108.0 nM and 46.4 nM for haPrP(29-
231), haPrP(90-231) and huPrP (23-230), respectively. The kinetic and thermodynamic binding 
constants of TH to the three forms of PrP were roughly comparable. The three PrP proteins share 
the same C-terminal domain, suggesting that interaction mainly occurs through the structured C-
terminal region of PrP, spanning residues 94-230, rather than the N-terminus. On the other hand, the 
SPR experiments demonstrate that TH(150-497) does not interact at all with any of the various 
forms of PrP. The SPR results support high-affinity binding between the C-terminal structured 
domain of PrP and the N-terminal regulatory domain of TH. 
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Fig: 25. SPR interaction between prion protein (PrP) and TH(1-497). (A) Association and dissociation curves over the TH-
immobilized chip at various huPrP(94-230) concentrations (red 0.5 μM, green 1.0 μM, magenta 2.0 μM, blue 5.0 μM and black 10 
μM, respectively). (B) SPR response (in arbitrary units) versus concentration of  huPrP(94-230). (C) Association and dissociation 
curves over the TH-immobilized chip at various concentrations of haPrP(29-231) (same colour code as in panel A). (D) SPR 
response (in arbitrary units) versus concentration of full-length haPrP(29-231). 
 
 
Cellular distribution of PrP and TH 
Interaction between PrP and TH in intact cells was evaluated by co-transfecting HeLa and CHO 
cells with expression plasmids for TH and human PrP chimeric proteins linked to yellow and cyan 
versions of the basic fluorescent protein. Not surprisingly, HeLa cells transfected with pcDNA3-PrP 
showed a predominantly plasma membrane expression, given that PrP is normally exported and 
linked to the plasma membrane via a GPI anchor after its translation (fig. 26A). When HeLa cells 
were transfected instead with pcDNA3-TH, the majority of TH expression was intracellular (fig. 
26B). Co-expression of these two proteins resulted in a strong decrease in plasma membrane PrP 
expression, along with an increased intracellular expression (fig. 26C). TH showed a similar 
topological localization (fig. 26D) and co-localization of the two proteins (fig. 26E). Analogous 
results were obtained with a fluorescent chimeric protein linking TH and human PrP, thus 
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confirming the observed decrease of plasma PrP expression and increased intracellular expression 
(fig. 27E). 
 
Fig: 26. Co-localization of huPrP and TH. Hela cells were transfected with pcDNA3-huPrP (A,C,D,) or with pcDNA3-huTH 
(B,C,D). After  transfection  the cells were incubated  with  anti-huPrP (3F4) and developed with FITC (A,C) or antibodies anti-TH  
and developed with TRIC (B, D) and developed with FITC and TRIC. Panel E: merged panels C and D. 
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Fig: 27. Co-localization of CFP-hPrP with YFP-TH. CHO cells were transfected with pECFP-hPrP (A,C,D) and wih pEYFP-TH 
(B,C,D). Panel E: merged panels C and D. 
Co-localization of the two proteins was also tested by transfecting CHO cells with pEGFP-PrP and 
pTH(1-497)-Ruby2, pTH(1-184)-Ruby2 or pTH(150-497)-Ruby2. We observed a clear co-
localization of GFP-PrP and TH(1-184)-Ruby2 or TH(1-497)-Ruby2 with an aincrease intracellular 
exspression of the prion protein, while no co-localization was evident for cells transfected to 
express PrP-GFP and TH(150-497)-Ruby2. In this case, the prion protein still localized to the 
plasma membrane. 
 68 
 
 
Fig: 28. Co-localization of GFP-PrP with TH(1-184)-Ruby2, TH(1-497)-Ruby2 and TH(150-497)-Ruby2 fusion proteins. 
CHO cells were transfected with plasmids pEGFP-PrP (all panels) and plasmids pTH(1-184)-Ruby2 (A,B), pTH(1-497)-Ruby2 (D,E) 
and pTH(150-497)-Ruby2 (G,H). After fixation cells were visualized using a TRIC filter for mRuby2 fusion proteins (red) and a 
FITC filter for GFP (green). Panel C: merged panels A and B. Panel F: merged panels D and E. Panel I: merged panels G and H. 
Scale bar: 20 μm. 
 
 
 
Moreover, when cells were transfected with  a PrP tagged to green fluorescent fusion prion protein 
(GFP-PrP), that normally localized to the plasma membrane of HeLa cells (fig. 29A), and were 
incubated with 50 mg/mL of TH recombinant protein, GFP-PrP translocated into the cells, 
indicating a cell surface interaction between these two proteins (fig. 29B). 
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Fig: 29. Tyrosine hydroxylase (TH) internalized GFP-hPrP. 
 Hela cells were transfected with pEGFP-PrP control (A) and also treated with 50 ug/mL of rhTH (B) for 4 h.  
 
In CHO cells transfected with pcDNA-TH and pcDNA-PrP, TH migrated as a 52 kDa species on 
immunoblots (fig. 30A). Its expression was not influenced by the presence of PrP. The minor bands 
at 28 kDa and 30 kDa represent degradation products of TH. Using the 3F4 antibody against PrP, 
lysates from PrP expressing cells showed a series of protein bands representing glycosylation state 
and the GPI anchor (fig. 30A). Co-expression of TH strongly decreased the presence of all PrP 
forms, in accord with the immunocytochemical data (fig. 30A). 
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Fig: 30. Gene and protein expression of tyrosine hydroxylase (TH) and prion protein (Prp). CHO  cells  were  transfected  with  
pcDNA  (control)  pcDNA-TH  or  pcDNA-PrP.  A) Western  blot was developed with anti-TH, or anti-PrP, and anti-GADPH. rhPrP 
(E.coli): reference standard of huPrP (23-230) produced and purified from E coli. B) RT-PCR  of  mRNA  for  TH,  PrP  and  
glyceraldehyde-3 phosphate  dehydrogenase  (GAPDH; control). CHO cells were transfected with pDNA (control), pcDNA-TH or 
pcDNA-PrP 
To verify if also the mRNA levels were affected by the co-transfection of plasmids encoding the 
two proteins, a Real-Time polymerase chain reaction (RT-PCR) was performed using the Qiagen 
one step RT-PCR kit and the following primers:  
417bp for human PrP: 5’cacccacagtcagtggaacaagccgag 3’and 5’accatgctcgatcctctctggtaatag 3’;  
407bp for human TH: 5’acgctgcctcgcccatgcactcccctg 3’and 5’ atgcgtgaggcatagctcctgagcttg 3’;  
401bp for hamster GAPDH: 5’tctgctgatgcccccatgtttgtgatg 3’and 5’ atgtcctcatacttggcaggtttctc 3’. 
The data obtained showed that the level of PrP mRNA did not change in the presence of plasmid 
expressing TH, indicating that modulation of PrP level is a post-translational event. PrP did not alter 
TH mRNA levels (fig. 30B) 
Co-precipitation assay 
Co-precipitation assay was performed as described in materials and methods transfecting the cells 
with pcDNA-TH  or  pcDNA-PrP. The sample were resolved by 12% SDS-PAGE, blotted onto a 
PVDF membrane and probed with anti-TH (1:1000) and anti-PrP (3F4) (1:1000) antibodies. 
However, attempts to recover TH and PrP by co-immunoprecipitation using these vector plasmids 
were unsuccessful, perhaps owing to only low amounts of PrP when the two proteins are co-
expressed. Co-immunoprecipitation, however, could be achieved when TAT-PrP was added to the 
cells (fig. 31A). Note the absence of immunoreactivity when primary antibody is omitted (fig. 31B). 
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In this manner TH could be recovered from cell lysates bound to PrP, confirming a strong 
interaction between these two proteins also ex vivo. 
 
 
Fig: 31. Co-immunoprecipitation of TH and TAT-His-Prp. 
CHO cells were transfected with pcDNA-TH or pcDNA3 (control) then treated for 4 h with 50 µg/mL of TAT-PrP. A) Cell lysates 
were prepared and incubated with NiTA-resin to sequester the His-tagged protein, and the purified proteins subjected to SDS-PAGE 
and immunoblotting with anti-TH (upper panel) and anti-PrP (lower panel) antibodies. B) Primary antibody omitted. 
 
TH activity assay 
The purified enzyme was first incubated to a final concentration of 600 nM, in a solution composed 
of 50 mmol/L HEPES (pH 7.0), 200 mmol/L (NH4)2SO4, 7 mmol/L DTT, 25 μg/mL catalase 
(Sigma-Aldrich) and 25 μmol/L (NH4)2Fe(SO4)2·6H2O. After 15 min equilibration at RT, the 
cofactor BH4 (Sigma-Aldrich) was added to 30 μmol/L. In the experiment with PrP, the latter (1:1 
molar ratio) was included from the middle of this equilibration time. The reaction was started by 
adding 50 μmol/L L-tyrosine (Sigma-Aldrich) from a 2.5 mmol/L stock solution. Incubation was 
carried out at 36°C for 2.5, 5, 10 or 20 min. Assays were stopped by adding 6 μL of 40% v/v 
trichloroacetic acid per 300 μL of reaction mixture, followed by incubation on ice. After 
centrifugation at 14000g for 10 min at 4°C, 100 μL of supernatant was injected into a C-18 column 
(Phenomenex) connected to an HPLC system (Agilent Technology). This was done to separate the 
reaction product L-DOPA (Sigma-Aldrich) from L-tyrosine. The mobile phase was 50 mmol/L 
sodium citrate, 50 mmol/L sodium acetate, 8% (v/v) methanol (pH 3.1); runs were performed at RT 
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with an isocratic flow of 0.2 ml/min. Elution was followed by UV absorbance (280nm). Product 
formation was also followed by fluorescence (excitation at 294 nm, emission at 330 nm). A 
standard curve, made with known concentrations of L-DOPA, allowed calculation of the yield of 
product formation from the intensity of fluorescence emission in the enzymatic reaction. The data 
obtained showed that incubation of both TH(1-497) and TH(150-497) forms in the presence of full-
length muPrP(23-231) or its TH interacting domain 90-231 did not affect TH catalytic activity 
 
Fig: 32. Neither the terminal domain nor full-length mouse prion prptein (PrP) affecttyrosine hydroxylase (TH) activity. 
(A) L-DOPA formation catalyzed by TH(1-497) with (ratio 1:1) or without (ratio 1:0) the C-terminal domain of mouse PrP (90-231). 
The reaction was stopped after 10 min. Error bars derive from propagation of three-measurement standard deviation. (B) L-DOPA 
formation catalyzed by TH(1-497) with (ratio 1:1) or without (ratio 1:0) full-length mouse PrP(23-231). The assay conditions differ 
from the standard one by the absence of DTT and the use of a higher concentration of BH4 (0.12 mM) and catalase (100 μg/mL). The 
reaction was stopped after 2.5 min. Error bars values derive from propagation of three-measurement standard deviation. 
 
 
 
 
 
 
 73 
 
Prion protein-Heat shock protein B8 interaction 
Construction of plasmids for HSPB8 
The eukaryotic expression plasmids encoding the human heat shock protein B8 wild type and the 
two mutants forms were kindly provided by Prof. A. Poletti, University of Milan, Milan, Italy. The 
HSPB8 human genes were amplified from the template using the following primers:  
5’  gcagctagcatggctgacggtcagatgcccttc 3’, 5’ gcagaattcactggtacaggtgacttccttgg 3’ 
The PCR products were cut with NheI and EcoRI and cloned into pRSETA (Invitrogen) and pTAT-
syn (already present in our laboratory) using the same restriction sites, to give respectively pRSET-
HSPB8 and pTAT-HSPB8. The HSPB8 and its mutant  from plasmid pRSETA were also sub-
cloned in pcDNA-mRuby2 (Addgene) using the following primers: 
 5’ atagatctcactggtacaggtgacttccttgg 3’,  5’  acaagcttatggctgacggtcagatgcccttc 3’  
 
The amplified product was cut with HindIII and EcoRI  before cloning in the same  restriction sites 
of pcDNA-mRuby2. In this way the nucleotide sequence encoding for fluorescent protein mRuby2 
was replaced by HSPB8 sequence with N-terminal histidine tag.  
The HSPB8 and its mutants was also cloned in plasmid pcDNA-mRuby2 between HindIII and 
BamHI using the following primers: 
5’  acaagcttatggctgacggtcagatgcccttc 3’, 5’ atagatcttgactggtacaggtgacttccttgg 3’.  
 
In this way we have obtained a fusion protein between the nucleotide sequence encoding for 
HSPB8 with nucleotide sequence for mRuby2. 
 
Recombinant protein expression and purification 
Plasmids pRSET-HSPB8wt, pRSET-HSPB8K141E, pRSET-HSPB8K141N, pTAT-HSPB8wt, 
pTAT-HSPB8K141E and pTAT-HSPB8K141N were introduced in BL21(DE3) E.coli cells. 
Expression of all recombinant proteins was carried out at 37°C for 3 hours after induction with 
IPTG.  
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Fig: 33. Protein expression of HSPB8, TATHSPB8 and their mutants. 
Plasmids were introduced in BL21(DE3) E.coli cells. Cells were grown at 37°C for three hours after IPTG induction. Samples were 
were diluted in Laemmli sample buffer (50 mmol/L Tris-HCl pH 6.8, 100 mmol/L DTT, 2% (w/v) SDS, 0.05% (w/v) bromphenol 
blue), heated for 5 min at 100°C and resolved by 13,5% SDS-page. 
 
All proteins were expressed with an N-terminal His-tag and purified following established 
procedures by HisTrap immobilized metal affinity chromatography (IMAC) FF (GE Healthcare). 
HSPB8wt, HSPB8K141E and HSPB8K141N proteins were purified using a sonication buffer 
composed of 100mM Tris-HCl, 20% glycerol, 274mM NaCl, 0,1% Pluronic acid, 0,02% Tween 20, 
10mM β-mercaptoethanol pH 8. The proteins were eluted in the same buffer plus 250mM imidazole 
and subsequently dialyzed against the same buffer without imidazole.  
TATHSPB8wt, TATHSPB8K141E and TATHSPB8K141N proteins were, instead, purified in 
denaturant conditions and dialyzed against 50mM phosphate buffer, 274mM NaCl, 20% Glycerol, 
0,1% Pluronic acid, 0,02% Tween 80, 10mm DTT pH 5,82.  
All purified proteins were aliquoted and stored at 80°C until used. 
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Fig: 34. SDS-page of the recombinant proteins purified in native conditions (left) for HSPB8wt and mutants, and in denaturant 
conditions for TATHSPB8wt and mutants (right). 
 
 
 
Fig: 35, SDS-page of the recombinant proteins dialyzed against 100mM Tris-HCl, 20% glycerol, 274mM NaCl, 0,1% Pluronic acid, 
0,02% Tween 20, 10mM β-mercaptoethanol pH 8 in the case of HSPB8wt and mutants, and 50mM phosphate buffer, 274mM NaCl, 
20% Glycerol, 0,1% Pluronic acid, 0,02% Tween 80, 10mm DTT pH 5,82 in the case of TATHSPB8 and mutants. 
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SDS-PAGE, Western blotting and dot-blot assay 
Mini SDS-PAGE was performed using the electrophoresis MiniVE (Amersham) system according 
to the manufacturer’s instructions. Protein samples were diluted in Laemmli sample buffer (50 
mmol/L Tris-HCl pH 6.8, 100 mmol/L DTT, 2% (w/v) SDS, 0.05% (w/v) bromphenol blue) and 
heated for 5 min at 100°C. Each well of a 13,5% SDS-PAGE was loaded with 1 μg total proteins. 
Separated proteins were transferred onto Immobilon-P polyvinylidene difluoride (PVDF) 
membranes (Millipore) with the mini VE System Blot Module (Amersham). For HSPB8 and its 
mutants the proteins were directly blotted onto the Bio-Dot Apparatus Microfiltration (Biorad) 
following the manufacturer’s instructions. For Far Western blots the membrane was incubated with 
10 mL of HSPB8wt (10 μg/mL) or its mutants in blocking buffer. Dot blot membrane was 
incubated with 10 mL of 10 μg/mL recombinant HuPrP. Membranes were washed 3 x 5 min with 
PBS/1% BSA, 0.1% Tween 20. HSPB8 bound to PrP or vice versa was detected by incubation with 
0.4 mg/mL of anti-his monoclonal antibody (H1029) (Sigma-Aldrich) or 0.5 mg/mL of anti-PrP 
mAb 3F4 (DAKO, Glostrup, Denmark) in blocking buffer for 1 h at RT followed by incubation 
with 50 ng/mL horseradish peroxidase-conjugated goat anti-mouse IgG mAb (Sigma-Aldrich) for 
45 min at RT. The blot was developed using the NBT/BCIP (Roche). 
 
 
 
Fig: 36. Far Western blot analyses of prion proteins with Heat shock porotein B8 and its mutants. 
Recombinant deletion form human PrP(94-230), human PrP, mouse PrP, hamster PrP, bovine PrP and human Dpl  were separated by 
13% SDS-PAGE. The same proteins are transferred on nitrocellulose and probed with 25 μg/mL recombinant human HSPB8wt, 
HSPB8K141E or HSPB8K141N  and developed with an anti-his antibody. 
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The data obtained from western blot showed that PrPs from human, mouse, hamster and bovine all 
interact with HSPB8 wild type and mutants. Human Doppel, instead, is not recognized by none of 
the three proteins. HSPB8wt and mutants specifically recognized PrP not being able to bind the 
other protein loaded as molecular weight markers. As for TH, far western blotting was effective 
only with PrP bound to the PVDF membrane and using HSPB8 as analyte; no interaction was 
observed when HSPB8 was bound to the PVDF membrane and PrP used as analyte. We, therefore, 
performed a dot-blot experiment. 
 
 
Fig: 37. Dot blot analyses of prion proteins with Heat shock protein B8 and its mutants. 
Serial dilutions (μg) of recombinant human HSPB8wt, HSPB8K141E, HSPB8K141N and albumin, were blotted onto nitrocellulose 
before probing with 20 μg/mL huPrP(23-230) followed by development with antibodies against huPrP (3F4). 
 
The results show that PrP is able to bind all the three forms of HSPB8 while it doesn’t recognize 
albumin. The interaction of PrP with HSPB8 wild type seems to be stronger than the interaction of 
the prion protein with the mutant forms of the heat shock protein.  
To further confirm HSPB8-PrP interaction and to identify the region of the prion protein involved 
in the binding, we performed a far western blot analysis using several deletion mutants of the 
protein. Sample resolved by SDS-page and blotted onto PVDF membrane, were incubated with 
10ml of HSPB8wt (10 μg/ml) in blocking buffer and developed with anti-His antibody.  
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Fig: 38. Far Western blot analyses of prion protein deletion mutants with Heat shock protein B8. 
Recombinant deletion form of human PrP were resolved by 13% SDS-PAGE. The same proteins were transferred on nitrocellulose, 
probed with 10 μg/ml recombinant human HSPB8wt  and developed with an anti-his antibody. 
 
HSPB8wt is able to recognize almost all the deletion forms of the prion protein, except for PrP125 
and PrP(23-90) indicating that the portion of the protein involved in the binding is the structured C-
terminal sequence of PrP while the N-terminal un-structured domain is not bound by the heat shock 
protein. 
PrP proteolysis by Proteinase K 
To further validate HSPB8-PrP interaction and identify possible in vitro consequences of this 
binding we performed an experiment to analyze PrP susceptibility to degradation mediated by 
proteinase K in the presence or absence of HSPB8 wild type or its mutants. It is, in fact, known that 
the  cellular isoform of the prion protein (PrP
C
) has an high susceptibility to proteinase K digestion, 
while the pathological isoforms of the protein (PrP
SC
) is resistant to the degradation.  
2μg of the murine prion protein were incubated with serial dilution of proteinase K in the presence 
or absence of 2μg of HSPB8wt and its mutants. The reaction was stopped by adding Laemmli 
sample buffer to the samples. The reaction products were heated for 5 minutes at 100°C and loaded 
into a 13,5% polyacrylamide gel.  
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Fig: 39. SDS-page of the proteolysis of the prion protein with proteinase K in the presence or absence of HSPB8wt and mutants 
form. 
The murine PrP is completely degraded after incubation with high concentrations of proteinase K 
and also lower amount of proteinase K are able to digest the major part of the prion protein. When, 
instead, the prion protein is incubated in the presence of the heat shock protein it is much less 
degraded. This protection is almost complete at low doses of proteinase K, but it is also present at 
higher doses. All the three forms of the HSPB8 are able to protect the prion protein but the mutant 
forms are less effective as we can see by the fact that at the highest dose of proteinase K they are 
not able to protect PrP from degradation. All these data together clearly demonstrate a protection 
from proteolysis by HSPB8 protein in the presence of protease. HSPB8 shows its chaperone activity 
protecting the prion protein from degradation. The mutant forms of the heat shock protein show a 
less effective, although present, protective action. 
 
Circular dichroism analyses 
A functional consequence of the interaction between the two proteins was evaluated following the 
denaturation process of the prion protein through circular dichroism in the presence or absence of 
HSPB8 in wild type form. 
As shown in fig. 40 the prion protein spectrum (dashed line) is characterized by two minimum at 
211 and 221 nanometers, indicating a prevalent α-helix structure; while the heat shock protein B8 
wild type spectrum (solid line) shows a prevalent unorder structur with a little incidence of a  -
sheet structure (minimum at 215 nanometers). 
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Fig: 40. CD spectra of the prion protein (dashed line) and the small HSPB8WT (solid line). 
 
The thermal denaturation process of the prion protein misured at 220 nanometers show a 
cooperative transition with a shift around 66°C. When prion protein was incubated in presence of 
the same molar amount of HSPB8 wild type (dashed line) the process of thermal denaturation 
occurred at lower temperature it was faster when compared to the prion protein alone (solid line). 
 
Fig: 41. CD spectra of the prion protein denaturation in the presence (dashed line) or absence (solid line) of the heat shock protein B8 
wild type. 
 
This shift in the prion protein denaturation spectrum is attribuible almost entirely to the prion 
protein with no incidence of the heat shock protein because, as shown in fig. 42, the HSPB8WT 
doesn’t undergo to big changes of structure under thermal denaturation. 
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Fig: 42. CD spectrum of heat shock protein B8 wild type denaturation. 
Interaction analysis on Biacore via surface plasmon resonance (SPR) 
The surface plasmon resonance experiments were conduct in the same conditions used for the PrP-
TH interaction evaluation. The huPrP(23-230) was immobilized on the sensor chip while HSPB8wt 
and its mutant forms were injected, as analyte, at various concentrations (within the range 10nM to 
10µM). The kinetic and thermodynamic association and dissociation constants obtained are shown 
in table: 
 
Ligand 
ka (1/Ms)  kd (1/s)  KD (M)  Rmax (RU)  Chi² (RU²)  U-value  
HSPB8 WT 
7111  0, 00261  3,67 10
-7
  606,6  350  2  
HSPB8 K141N 
6550 0, 00270 4,12 10
-7
  667,3 797 3 
HSPB8 K141E 
5408 0, 00295 5,46 10
-7
  693,0 980 4 
 
Fig: 43. Kinetic parameters and dissociation constants for the interaction of HSPB8 wild type and mutants with PrP.  
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Thermodynamic evaluation of the interaction between HSPB8 and PrP yielded equilibrium 
dissociation constants (KD) of 367nM, 412nM and 546nM for wild type HSPB8, HSPB8K141N 
and HPB8K141E, respectively. Sensorgrams for the interaction of PrP with HSPB8wt, K141N and 
K141E are shown in fig. 44, while fig. 45 shows the dose-response SPR signal versus the 
concentration of heat shock proteins. 
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Fig: 44. Association and dissociation curves over the PrP-immobilized chip at various concentrations of HSPB8wt, HSPB8K141N 
and HSP8K141E (from top to bottom). 
 
The evolution of the response as a function of the concentrations of HSPB8wt and its mutants tends 
to a plateau at concentrations greater than 5µM, index of specificity in the interaction between the 
PrP and the HSPB8. 
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Fig: 45. Response (in arbitrary units) versus concentration of  HSPB8wt, HSPB8K141N and HSP8K141E, respectively. 
 
The data obtained show a strong interaction between PrP and all the three forms of the small heat 
shock protein. However, the interaction of the wild type HSPB8 with the prion protein results to be 
stronger than both the mutants forms, according with the western blot and dot-blot data. 
 
Cellular expression of PrP and HSPB8 
Interaction between PrP and TH in intact cells was evaluated by co-transfecting CHO cells with 
expression plasmids for HSPB8 and human PrP. 
In CHO cells transfected with pcDNA-HSPB8 and pcDNA-PrP, HSPB8 migrates as a 29 kDa 
species on immunoblots because in this case HSPB8 have a N-terminal tail with 14 aminoacids 
conteining 6 histidine residues necessary for immunoblot assay using His-tag monoclonal antibody.  
PrP shows different bands corresponding to the various glycosilation states of the protein. Co-
expression of HSPB8 strongly decreased the presence of all PrP forms.  
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Fig: 46. Protein expression of heat shock protein (HSPB8) and prion protein (PrP). 
CHO  cells  were  transfected  with  pcDNA  (control),  pcDNA-HIS-HSPB8 or  pcDNA-PrP.  Western  blot was developed with 
anti-His, or anti-PrP, and anti-GADPH. 
 
In particular, it seems that the wild type HSPB8 has an effect on PrP comparable with that of the 
HSPB8K141E, while the reduction of prion protein expression mediated by HSPB8K141N is much 
less noticeable. The co-expression of the two protein also strongly reduced the level of expression 
of all the three forms of the small heat shock protein. Once again the K141N mutated form of the 
protein is the less affected by the reduction of cellular expression level. 
To verify if the effects of the heat shock protein on the prion protein are dependent on the 
transfection of the plasmid vector, we test if the same effect is reached when CHO cells are treated 
with TATHSPB8 wild type and mutants. To do this we firstly tested the half life of the protein in 
the cells. CHO cells were treated with 10µg/ml of recombinant TATHSPB8 wild type and collected 
3, 5, 24, 36 and 48 hours after the addition of the protein. Samples were loaded into a 13,5% SDS-
page and transferred onto a PVDF membrane developed with anti-His or anti-PrP antibodies. 
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Fig: 47. Time course of the TATHSPB8 wild type in CHO cells. 
Our results show that TATHSPB8 wild type is able to enter the cells within three hours after the 
addiction to the culture medium. The protein remains detectable in the cells for up to 48 hours. 
The experiments were repeated  treating CHO cells with 10µg/ml of recombinant TATHSPB8 and 
10µg/ml of recombinant TATPrPGFP11 or with the same amount of TATPrPGFP11 alone. 
Samples were colleted after 3, 5, 24, 36 and 48 hours from the addition of the proteins and loaded 
into a 13,5% SDS-page and transferred onto a PVDF membrane developed with anti-His antibody 
for the detection of the heat shock protein 3F4 antibody for the detection of the prion protein. 
 
Fig: 48. Time course of the TATHSPB8 wild type and TATPrPGFP11 proteins in CHO cells. 
Data from western blot show a slight protection of prion protein degradation mediated by the co-
expression of the heat shock protein. 
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Cellular distribution of PrP and HSPB8 
Interaction between PrP and HSPB8 in intact cells was evaluated by co-transfecting CHO cells with 
expression plasmids for a GFP tagged prion protein (pEGFP-PrP)  (Negro et al. 2000) and a 
mRuby2 tagged human HSPB8 wild type and mutants. Once again, PrP showed a predominantly 
plasma membrane expression (fig. 49D), while the heat shock proteins seems to accumulate 
intracellularly and to form small aggregates that are much more evident for the mutant forms 
K141E and K141N (fig. 49B and C, respectively) than for the wild type protein (fig. 49A).  
 
 
 
 
                     
Fig: 49. Cellular localization in CHO cells of HSPB8-mRuby2 wild type, K141E and K141N (panel A,B,C respectively) and GFP-
PrP (panel D). 
Co-expression of the two proteins resulted in a strong decrease in plasma membrane PrP 
expression, along with an increased intracellular expression. The switch from a plasma membrane 
expression to an intracellular expression was particularly evident when the co-expression involved 
PrP and the wild type form of the small heat shock protein, while it was less clear when the prion 
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protein was co-expressed with the mutant forms of HSPB8, especially for what concern 
HSPB8K141N.  
The intracellular localization of all forms of the small heat shock protein was unaffected. The co-
expression of the two proteins resulted in a strong co-localization of HSPB8 wild type with the 
prion protein. This co-localization is also present with the mutant forms of the heat shock protein, 
but with a less extent.  
 
Fig: 50. Co-localization of GFP-PrP with HSPB8-mRuby2 wild type and  mutants. 
CHO cells were co-transfected wih pHSPB8wt-mRuby2, pHSPB8K141E-mRuby2 and pHSPB8K141N-mRuby2 (higher row) and 
with pcDNAGFP-PrP (middle row). Lower row merges the upper panels. 
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DISCUSSION AND FUTURE PERSPECTIVE 
Our study is the first description of two specific and neurologically relevant interactions involving 
the prion protein, known to be the major player in a group of  diseases involving the central nervous 
system collectively named transmissible spongiform encephalopathies (TSEs). The novel-identified 
interaction partners of PrP are tyrosine hydroxylase (TH), enzyme that catalyzes the first and rate 
limiting step in the biosynthesis of catecholamines, and heat shock protein B8 (HSPB8), member of 
the small heat shock protein family, that seems to be of special interest in those diseases that, like 
TSEs, are characterized by the accumulation of misfolded proteins. 
Being two cytoplasmatic proteins, TH and HSPB8, would not be expected a priori to be accessible 
to PrP, prevalently expressed in the cell as a plasma membrane GPI-anchored protein. Anyway,  
numerous studies report the presence of a cytosolic PrP form in subpopulations of neurons in the 
hippocampus, neocortex, and thalamus (Mironov et al. 2003, Fioriti et al. 2005, Ma et al. 2002) in a 
variety of condition including stress (Orsi et al. 2006). Moreover, it is clear from the literature that 
PrP can interact with numerous intracellular proteins, most of them located in the cytosol. Among 
them we can find synapsin-1b, neuroglobin, 14-3-3 protein, tubulin and mahogunin (Nieznanski 
2010 for review). Thus, it is possible to postulate that particularly at pathologic conditions,  
intracellular  proteins  may be exposed to interactions with PrP or that they can cross with the prion 
protein during its synthesis and translocation to the plasma membrane. 
 
Prion protein-Tyrosine hydroxylase interaction 
Western blotting, dot blot and surface plasmon resonance analysis indicate a strong interaction 
between PrP and tyrosine hydroxylase. The binding occurs with PrP of various species while the 
human doppel protein, sharing the same structure with PrP, is not recognized by the TH. TH  
recognizes PrP through its N-terminal  regulatory  domain  TH(1-152), while  the  catalytic  domain  
is  not  involved  in  binding.  On  the  other  hand, PrP recognizes  TH through  its  C-terminal  
domain  PrP(90-230),  while  the  N-terminal  domain  is  not  involved  in binding.  The SPR 
analysis show KD values falling in the range 2.2-5.0 nM when PrP is immobilized on the sensor  
chip  and  in  the  range  46.4-108  nM  when  TH  is immobilized  on  sensor chip.  The  two sets  
of  measurements provide  strong  support  for a PrP-TH interaction  even  though  with  slightly  
different  affinities.  When  PrP  is  covalently  immobilized through its -NH2  groups, its C-terminal 
interacting domain (94-231) is entirely exposed and hence prone  to  recognize  and  bind  TH.  
Likewise,  when  TH  is  immobilized,  its  N-terminus  covalently binds to the carboxymethyl 
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dextran chip-matrix and hence is less exposed to PrP, resulting in a less productive binding. In 
addition, re-folded PrP is recognized by TH on far Western blot, while PrP  recognizes  TH  only  
when  immobilized  by  dot-blot  technique,  indicating  that  both  proteins must  be  folded  for  the  
recognition  and  binding.  All these data together indicate that the interaction between prion protein 
and tyrosine hydroxylase is characterized by high affinity, is dependent of structured region of the 
proteins and is both sequence and structure specific. 
The interaction between the two proteins is confirmed by the immune-localization data in intact 
cells, where they show a co-localization pattern. In particular, when TH is co-expressed with PrP, 
the latter is involved in a switch from a prevalent plasma membrane-expression to a prevalent 
intracellular expression while the TH topological localization is not affected. Data from western 
blotting reveal that co-expression of the two proteins significantly reduced the level  of expression 
of all the cellular forms of the prion protein, while the level of expression of tyrosine hydroxylase 
are not affected. Moreover, RT-PCR analyses show that while the protein expression level of PrP 
are down-regulated, the mRNA levels don’t change after co-transfection with TH, suggesting that 
the modification of prion protein levels is a post-translational event. The recovery of TH by co-
immunoprecipitation supports the evidences of a cellular interaction involving the two protein. The 
fact that this co-immunoprecipitation is achieved only when TAT-PrP is added to the cell and not 
when TH and PrP are simply co-transfected, is probably due to the very low amount of PrP in the 
cell when TH is expressed.  
Our finding seems to be supported by previous studies on scrapie infected mice and dopaminergic 
neurons. Yun et al. found that TH-immunoreactive neurons in the substantia nigra and locus 
ceruleus are significantly decreased in scrapie-infected mice compared to controls (Yun et al. 1998) 
while Ford and colleagues showed that while  dopaminergic  neurons  of  the  substantia  nigra 
express  high  levels  of  TH  protein,  these  same  cells  display  a  high  PrP  mRNA  content  but  
no detectable PrP
C  
protein (Ford et al. 2002). The reason for this disparity between mRNA and 
protein level  of  PrP
C
  within  the  CNS  is  not  known,  although  the  exceptionally  fast  turnover  
of  Prp
C
  in cerebellar granule cells has been suggested to account for this disparity (Parizek et al. 
2001). This finding is in line with the altered cellular distribution and expression of PrP observed in 
our experiments when  PrP  is  co-expressed  with  TH.   
The observation that PrP does not affect TH activity in vitro could be due to the fact that PrP binds 
the regulatory, but not catalytic domain of TH. Several proteins bind to TH, one of the most studied  
being  14-3-3.  Also  in  this  case,  binding  between  14-3-3  and  TH  occurs  through  the  N-
terminal  regulatory  domain  of  TH  (Halskau  et  al.  2009),  with  an  affinity  comparable  to  that 
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observed  for  PrP  towards  TH  (Kleppe  et  al.  2001).  The 14-3-3  protein  does  not  influence  
TH catalytic  activity  directly,  but  rather  the  latter’s  accessibility  to  kinases  and  phosphatases.  
For example, PrP could mask the TH N-terminal domain in such a way as to prevent 
phosphorylation and activation. α-Synuclein, which is involved in Parkinson disease, can also 
modulate TH activity by  inhibiting  its  phosphorylation  and  consequently  dopamine  synthesis  
(Peng  et  al.  2005).  PrP itself  undergoes  phosphorylation  and  is  capable  of  modulating  the  
phosphorylation  of  several kinases (Negro et al. 2000; Meggio et al. 2000). One cannot exclude 
that PrP may modulate TH activity in a similar manner. 
All these data seems to suggest important physiological and pathological roles for TH-PrP 
interaction and is possible to hypothize some scenarios involving this binding. For example one  
might  speculate  that  in  Parkinson  disease,  characterized  by  a  loss  of dopaminergic neurons, 
PrP acts to sequester TH released from compromised neurons and hence supports  the  remaining  
surviving  cells. On the other hand it is also possible that in physiological condition TH could be a 
direct modulator of PrP expression and distribution inside the cell, while in pathological conditions 
the over-expression or down-regulation of one of the protein leads to an alteration of the binding 
resulting in pathological processes such as the accumulation of misfolded PrP inside the cell. This  
hypothesis  is  in  line  with  recent  ideas  suggesting that protein-protein interaction can ameliorate 
protein-misfolded diseases  allowing the normal biological function of proteins and preventing their 
aggregation and accumulation (Pastore and Temussi 2012). 
 
Fig: 51. Schematic representation of the protein fate. The interaction with a partner allows the normal function of the protein, while 
the absence of the binding partner leads to aberrant aggregation of the protein (Pastore and Temussi 2012). 
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Our data show that TH could be a direct modulator of PrP expression and, conceivably, decreased 
TH expression  could  increase  PrP  levels. To further strengthen this idea we’re going to express 
short interference RNA for tyrosine hydroxylase in cells expressing high amount of the enzyme and 
very low amount of prion protein. If our statements are true, the inhibition of TH expression 
mediated by siRNA should lead to an increase of PrP expression and localization on the plasma 
membrane. Moreover, future  studies  should be  directed  to  determine  if  these relationships 
occur also in diseases human brain. 
Prion protein-Heat shock protein B8 interaction 
Western blotting, dot blot and surface plasmon resonance analyses indicate a strong interaction 
between PrP and the small heat shock protein HSPB8. As in the case of tyrosine hydroxylase, the 
heat shock protein recognizes PrP of various species, but is unable to bind the human doppel 
protein. PrP  recognizes  the heat shock protein through  its  C-terminal  domain  PrP(90-230),  
while  the  N-terminal  domain  is  not  involved  in binding.  Western blotting analyses reveal that 
the interaction occurs not only with the wild type form of the protein, but also with the two 
pathological mutants, even if with less strength. Western blotting analysis with the three forms of 
the heat shock protein immobilized on the PVDF membrane and PrP used as analyte are not 
possible because of the incapability of the proteins to refold on the membrane. Dot-blot 
experiments, that don’t need any denaturation steps, confirm the interaction between the heat shock 
protein forms and the prion protein, underling that it is stronger for the wild type forms than for the 
mutant forms. The SPR analysis show KD  values falling in the range 367nM- 546nM when PrP is 
immobilized on the sensor chip. The quantitative data of the surface plasmon resonance confirm the 
results obtained with western blotting and dot-blot indicating that the stronger interaction occurs 
between the wild type heat shock protein and the prion protein, while the weakest binding is that 
between PrP and the K141E mutant form of the HSPB8. As expected, the mutations associated with 
the development of distal motor neuropathy type II and Charcot-Marie-Tooth disease type 2 show 
less binding affinity for the prion protein with respect to the wild type protein.  
In order to verify if this lower affinity leads to some functional changing we tested the in vitro 
protection of PrP degradation mediate by proteinase K. Our results indicate that HSPB8 is always 
able to protect the prion protein from proteolysis but that the mutant forms are less performing, in 
particular for what concern HSPB8K141N. It is possible that the single amino acid substitution of 
the mutant forms of the heat shock protein not only affects the strength of the interaction  with PrP 
but it also uncovers a cleavage site for the proteinase K on the PrP sequence leading to a faster 
degradation of the protein.  
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Data from circular dichroism has also shown that the incubation with the small heat shock protein 
B8 wild type is able to improve the prion protein denaturation under heat stress conditions. 
The interaction between the prion protein and the heat shock protein is confirmed by the immune-
localization data in intact cells, where they show a co-localization pattern. When the HSPB8 wild 
type or mutant forms are co-expressed with PrP, the latter undergoes to a change from a plasma 
membrane GPI-anchored expression to a prevalent intracellular expression that overlap the 
expression of the heat shock protein. This changing is particularly clear in the case of the wild type 
heat shock protein, while is less clear with the pathological forms of the protein, especially for what 
concern the lysine to asparagine substitution. It is intriguing that the various forms of the heat shock 
protein show different behaviors also where they are expressed alone in intact cell.  HSPB8, in fact, 
tends to form small aggregates inside the cell. The number and size of these aggregates becomes 
bigger for the mutant forms of the protein. Once, again, the K141N show the worst phenotype. One 
might speculate that the wild type form of the protein exist in a semi-soluble state inside the cell and 
that the mutation affecting the lysine at position 141 makes the mutants less soluble leading to their 
aggregation inside the cell.  
Western blotting data show that when the two proteins are co-expressed in intact cells, the protein 
expression of both PrP and HSPB8 decreased. This down-regulation is quite comparable for the 
wild type heat shock protein and for the lysine to glutamic acid substitution at position 141, while 
for the K141N mutation we can observe a different phenotype in which the level of heat shock 
protein are extensively down-regulated, while the PrP protein expression levels are affected only 
minimally. These results are in good agreement with the in vitro results and indicate that the 
interaction between prion protein and heat shock protein is able to modulate the expression and 
localization of both the proteins.  It is intriguing that the K141N  mutant, even if  SPR data indicate 
that it doesn’t have the lower affinity for the prion protein, shows the worst phenotype in all the 
experiments conducted.  It is possible to postulate that heat shock protein acts on PrP in the same 
way it was found to act with polyglutamine proteins leading to their degradation by stimulating 
macroautophagy. Our findings suggest that this process is dependent not only on the strength of the 
interaction but also on the nature of the amino acid substitution that can alter the physical-chemical 
property of the heat shock protein or its interaction with other proteins inside the cell. One may 
speculate that heat shock protein has a dual function in the cell with respect to the prion protein: on 
one way it acts as a molecular chaperone, helping the proper folding of the prion protein, on the 
other way it facilitates the turnover of the protein and the degradation of misfolded PrP maintaining 
the levels of the prion protein at a physiological state and preserving its biological function. It 
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seems reasonable that the mutations associated with the development of neuropathies, in particular 
in the case of the lysine to asparagines substitution, change not only the strength of the binding with 
the prion protein but also the physical-chemical properties of the heat shock protein that tends to 
aggregate inside the cell. It is possible that this aggregation state may prevent the chaperone activity 
of the heat shock protein and its capacity to stimulate the degradation of misfolded protein leading 
to the accumulation of intracellular prion protein that might cause neurological disorders.  
An opposite effect is obtained when cells are treated with TATPrPGFP11 and TATHSPB8WT. In 
this case, western blot analyses reveal that the heat shock protein co-expression is able to protect the 
prion protein from the degradation, leading to higher yields of the protein inside the cells. This data 
reflect the protection of the prion protein from the in vitro degradation by the proteinase K mediated 
by the heat shock protein. The inconsistency with the results obtain with the co-transfection of the 
proteins in intact cells can be due to the different fate of the protein inside the cells. When PrP is 
tranfected, in fact, it is subjected to a series of translocation and post translational modification 
(including its translocation to the Golgi apparatus and its glycosilation) leading to a plasma 
membrane localization, while when the prion protein enter the cell via Tat it is immediately 
available for the degradation ad the small heat shock protein can bind the prion protein preventing 
its turnover. In light of these results, it is reasonable that the heat shock protein may function as a 
molecular chaperone on the prion protein, being able in different conditions or concentrations of  
both preventing or helping its clearance inside the cells.  
As in the case of tyrosine hydroxylase future  studies  should be  directed  to  determine  if  these 
relationships between PrP and heat shock protein occur also in diseases human brain. If this were 
confirmed, the wild type heat shock protein would be a promising target for a therapeutic approach 
aimed to prevent the aggregation and accumulation of aberrant PrP molecules, which is at the basis 
of all the transmissible spongiform encephalopathies.  
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